Podcasts about j clin invest

*Show-Notes enthalten Werbung Inositol-Komplex: (4g) https://amzn.to/4kL5NGz Ausleitung überschüssiges Östrogen/Lebersupport: https://www.big-zone.de/Big-Zone-Hepa-180-Kapseln/0-7 und https://www.big-zone.de/Big-Zone-NAC-240-Kapseln/SW10038 (-10% mit Larry10) GDA: https://www.big-zone.de/Big-Zone-Invictus-G.D.A-90-Kapseln/InvictusGDA (-10% mit Larry10) Fem2+: https://www.big-zone.de/Big-Zone-Fem2-210g-Dose/SW10063.1 (-10% mit Larry10) Vitafuse: https://www.big-zone.de/Big-Zone-Vitafuse-750g-Dose/SW10027.1 (-10% mit Larry10) Shield: https://www.big-zone.de/Big-Zone-Shield-270g/BZShield (-10% mit Larry10) Ceylon-Zimt: https://amzn.to/3ZymFIz Mönchspfeffer: https://amzn.to/454sf98 Insulinfasten eBook: https://larissa-reinelt.com/?product=insulin-fasten-ebook Growth Convention: https://growthconvention.de (-10% mit LARRY) Blutbildanalyse: https://calendly.com/larissareinelt/blutbild-analyse?month=2025-06 Astaxanthin: https://amzn.to/43vTeYs Studien-Auszug: Ottarsdottir K et al.: Sex hormone binding globulin and development of insulin resistance: a longitudinal study. EASD 2018, abstract 43 Ketogenic Diet as Medical Prescription in Women with Polycystic Ovary Syndrome (PCOS), Barrea et. Al 2023 Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management, Fashchi et. Al. 2007 The interplay between PCOS pathology and diet on gut microbiota in a mouse model, Rodriquez Paris et. Al. 2022 Schriever SC, Kabra DG, Pfuhlmann K et al. Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity. J Clin Invest. 2020 Aug Inositol / Vitafuse : ML Croze et al., 2013, J.E. Nestler et al., 1999; D. Costantino et al., 2009, HJ Kim et al., 2012, C. Celentano et al., 2016; R. D'Anna et al., 2015, (OptiFiT)-Studie, 2019,

¿Ozempic es solo para bajar de peso? La respuesta es mucho más profunda. En este video te explico, con evidencia científica clara, lo que realmente sucede en tu cuerpo cuando tomas Ozempic (semaglutida): -Cómo regula el apetito en tu cerebro -Cómo mejora tu digestión y metabolismo -Por qué reduce el "ruido de comida" -Y cómo puede devolverte el control sobre tu salud metabólica ¡Suscríbete a este podcast en tu plataforma favorita para no perderte nada!

Thyroid Talk with Dr. Angela Mazza, DOShow Notes Episode 35; Recorded: 11-8-2024Cellular Longevity: Part 2 of Longevity SeriesHost: Dr. Angela Mazza, DOCo-host: Dawn SheffieldI'm Dr. Angela Mazza, D.O., a thyroid, endocrine, and metabolism specialist with a private practice in Central Florida.  My goal for this podcast is to define and demystify the thyroid gland, and thyroid-related medical conditions.  Here's some of what we covered today, not necessarily in this order:·        Genetics vs. epigenetics·        The “Hallmarks of Aging”·        Misconceptions about aging·        The Japanese concept of Ikigai·        Supplements that can support healthy aging·        Social isolation can become just as deadly as cancer·        Healthspan: a healthy, productive life--not just a long life          ·        At any age, work toward having a long, healthy life--anywhere in the world.  My book, Thyroid Talk: An Integrative Guide to Optimal Thyroid Health, is available on Amazon.  For information on the related Webinar and online master course, see thrivethyroid.com.  Or forward your name and email to thyroidtalk.mazza@gmail.com or to our website: metaboliccenterforwellness.com  Send your comments, show ideas, and questions to thyroidtalk.mazza@gmail.com    See the website at metaboliccenterforwellness.com, our YouTube channel at: Dr. Angela Mazza; as well as Facebook and Instagram.  The topic of our next episode, number 36, is living life without a thyroid gland. Citations, references, additional information:Buettner D., Skemp S. Blue Zones: Lessons From the World's Longest Lived.  Am J Lifestyle Med. 2016 Jul 7;10(5):318-321.Kaeberlein M. How healthy is the healthspan concept? Geroscience. 2018 Aug;40(4):361-364. doi: 10.1007/s11357-018-0036-9. Epub 2018 Aug 6.Mazza, A.  Longevity & Cellular Aging: An Integrative Approach to Healthy Aging.  Pure Encapsulations Webinar; Sep 18, 2024.Mazza A.  Thyroid Talk: An Integrative Guide to Optimal Thyroid Health.  Available now on Amazon.National Geographic.  November 2005.Rowe J., Kahn R. 1987; Science.Garcia H, Miralles F.  IKIGAI The Japanese Secret to a Long and Happy Life.  Copyright 2016 Hector Garcia and Francesc Miralles.  Translation Copyright 2017 by Penguin Random House LLC.  Dai H, Sinclair DA, Ellis JL, Steegborn C. Pharmacol Ther. 2018 Aug;188:140-154Zhou DD, et al. Oxid Med Cell Longev. 2021 Jul 11;2021:9932218.Zhang L, et al. J Clin Invest. 2022 Aug 1;132(15):e158450. Ke R, et al. Cell Biol Int. 2018 Apr;42(4):384-392. doi: 10.1002/cbin.10915. Epub 2018.Szewczuk M, et al. Mol Biol Rep. 2020 Nov;47(11):9075-9086.Steinberg GR, Hardie DG. Nat Rev Mol Cell Biol. 2023 Apr;24(4):255-272.Don't forget to ask your healthcare provider about any specific questions regarding your wellness.  This podcast is meant for educational purposes only.Copyright 2024 Dr. Angela Mazza DO.  Thyroid Talk with Dr. Angela Mazza, DO.  All rights reserved. Check out our YouTube channel - Dr. Angela Mazza, our website at Metabolic Center for Wellness, our FaceBook and our Instagram page.

In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology? Intro 0:11 Recap of part 1 & 2 0:28 In this episode 1:44 Cyclooxygenase 2 (COX-2) and the rat experiment 3:12 What do we know about the prostaglandins? And what about COX-2 7:54 What does prostacyclin do? 10:33 The first COX-2 inhibitor: VIOXX 10:56 What is COX-2 doing?: Pfizer and Merck 12:15 Two more NSAID studies: colon cancer, Alzheimer's disease and COX-2 inhibitors 18:41 VIOXX: Why is myocardial infarction risk occurring? 22:34 Animal models and the Goldilocks theory of thromboxane and prostacyclin 23:49 PRECISION trial 30:25 Rheum + Boards 37:14  Thanks for listening 37:32 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Anderson GD, et al. J Clin Invest. 1996;doi:10.1172/JCI118717. Funk CD, et al. J Cardiovasc Pharmacol. 2007;doi:10.1097/FJC.0b013e318157f72d. Hennan JK, et al. Circulation. 2001;doi:10.1161/hc3301.092790. Krumholz HM, et al. BMJ. 2007;doi:10.1136/bmj.39024.487720.68. Nissen SE, et al. N Engl J Med. 2016;doi:10.1056/NEJMoa1611593. Disclosures: Brown reports no relevant financial disclosures.

Contributor: Travis Barlock MD Educational Pearls: Clinical picture: A patient comes in with altered mental status, tachycardia, fever, elevated T4, and low TSH. What's the diagnosis?... Thyrotoxicosis secondary to Graves' Disease. How do you treat thyrotoxicosis? First, give a beta-blocker such as propranolol. This suppresses the elevated adrenergic activity. Second, give a thionamide such as propylthiouracil (PTU) or methimazole. This decreases the synthesis of new thyroid hormone. PTU is preferred because it also blocks the conversion of T4 to T3. Third, give an iodine solution such as potassium iodide. This blocks the release of thyroid hormone through a mechanism called the Wolff-Chaikoff effect. Note, this should be given about an hour after the PTU/methimazole to ensure iodine cannot be taken up and used to synthesize more thyroid hormone in individuals with toxic adenoma or toxic multinodular goiter. Fourth, give a glucocorticoid such as hydrocortisone. This will reduce thyroid hormone conversion from T4 to T3 and treat any concurrent adrenal insufficiency. References Abuid J, Larsen PR. Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. J Clin Invest. 1974 Jul;54(1):201-8. doi: 10.1172/JCI107744. PMID: 4134836; PMCID: PMC301541. Cooper DS, Saxe VC, Meskell M, Maloof F, Ridgway EC. Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J Clin Endocrinol Metab. 1982 Jan;54(1):101-7. doi: 10.1210/jcem-54-1-101. PMID: 6274892. Das G, Krieger M. Treatment of thyrotoxic storm with intravenous administration of propranolol. Ann Intern Med. 1969 May;70(5):985-8. doi: 10.7326/0003-4819-70-5-985. PMID: 5769631. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am. 2006 Dec;35(4):663-86, vii. doi: 10.1016/j.ecl.2006.09.008. PMID: 17127140. Tsatsoulis A, Johnson EO, Kalogera CH, Seferiadis K, Tsolas O. The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol. 2000 Mar;142(3):231-5. doi: 10.1530/eje.0.1420231. PMID: 10700716. Summarized by Jeffrey Olson, MS2 | Edited by Jorge Chalit, OMSII

Welcome to Olink Proteomics in Proximity Podcast! Below are some useful resources from this episode: Highlighted publication: Grasberger H, Magis AT, Sheng E, Conomos MP, Zhang M, Garzotto LS, Hou G, Bishu S, Nagao-Kitamoto H, El-Zaatari M, Kitamoto S, Kamada N, Stidham RW, Akiba Y, Kaunitz J, Haberman Y, Kugathasan S, Denson LA, Omenn GS, Kao JY. DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk. J Clin Invest. 2021 May 3;131(9):e141676. doi: 10.1172/JCI141676. PMID: 33651715; PMCID: PMC8087203. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087203/Highlighted platform that was used to measure proteins in this study with a qPCR readout (Olink® Target 96): https://olink.com/products-services/target/ Learn more about the Crohn's & Colitis Foundation, which is non-profit, volunteer-fueled organization dedicated to finding cures for Crohn's disease and ulcerative colitis: https://www.crohnscolitisfoundation.org/aboutIn the fall of 2021, Dr. Andrés Hurtado-Lorenzo spoke at a Boston Olink event, and his 25-minute presentation is available here where he discusses the discovery and follow-up work with both RNA and protein biomarkers for Crohn's Disease: https://7074596.fs1.hubspotuserconten...Olink® Insight is an open-access resource, which aims to support the user throughout the Olink user journey, starting from product selection and study setup to post-run analysis and visualization of data output. Features include a pathway browser to reveal and understand connections between proteins and human biology, a publication browser, automatic annotations, and access to exclusive data sets. Sign up for free: https://insight.olink.com/ Here is general information about inflammatory bowel disease (IBD) from the U.S. Centers for Disease Control and Prevention (CDC): https://www.cdc.gov/ibd/what-is-IBD.htm#:~:text=Inflammatory%20bowel%20disease%20(IBD)%20is,damage%20to%20the%20GI%20tract. Here is general information from GeneCards about DUOX2, one of the protein biomarkers identified in this study: https://www.genecards.org/cgi-bin/carddisp.pl?gene=DUOX2Here is general information from GeneCards about IL-17C, one of the protein biomarkers identified in this study: https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL17C&keywords=il17cWould you like to subscribe to the podcast on your favorite player or app? You can do so here: Apple Podcasts: https://apple.co/3T0YbSm Spotify Podcasts: https://open.spotify.com/show/2sZ2wxO... Google Podcasts: https://podcasts.google.com/feed/aHR0... Amazon Music: https://music.amazon.com/podcasts/d97... Podcast Addict: https://podcastaddict.com/podcast/409... Deezer: https://www.deezer.com/show/5178787 Player FM: https://player.fm/series/series-3396598 In case you were wondering, Proteomics in Proximity refers to the principle underlying Olink Proteomics assay technology called the Proximity Extension Assay (PEA), and more information about the assay and how it works can be found here: https://bit.ly/3Rt7YiY For any questions regarding information Olink Proteomics, please email us at info@olink.com or visit our website: https://www.olink.com/ WHAT IS PROTEOMICS IN PROXIMITY?Proteomics in Proximity discusses the intersection of proteomics with genomics for drug target discovery, the application of proteomics to reveal disease biomarkers, and current trends in using proteomics to unlock biological mechanisms. Co-hosted by Olink's Dale Yuzuki, Cindy Lawley and Sarantis Chlamydas.

Join FlightBridgeEDs new Chief Medical Director, Mike Lauria, as we launch the FlightBridgeED MDCast. Dr. Lauria will hijack these episodes for a new perspective on current topics in critical care medicine. In this episode, Dr. Lauria looks at Eric's previously published podcast [episode 224] on ASA Overdose and gives his insight, practical application, and overall thoughts on these difficult-to-manage patients. Don't miss this episode! So much good stuff! Please like, subscribe, and leave any questions or comments. References for Acute Salicylate Intoxication Anderson RJ, Potts DE, Gabow PA, Rumack BH, Schrier RW. Unrecognized adult salicylate intoxication. Ann Intern Med. Dec 1976;85(6):745-8. doi:10.7326/0003-4819-85-6-745 Chyka PA, Erdman AR, Christianson G, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(2):95-131. doi:10.1080/15563650600907140 Dargan PI, Wallace CI, Jones AL. An evidence-based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J. May 2002;19(3):206-9. doi:10.1136/emj.19.3.206 Delaney TM, Helvey JT, Shiffermiller JF. A Case of Salicylate Toxicity Presenting with Acute Focal Neurologic Deficit in a 61-Year-Old Woman with a History of Stroke. Am J Case Rep. Feb 15 2020;21:e920016. doi:10.12659/AJCR.920016 Espírito Santo R, Vaz S, Jalles F, Boto L, Abecasis F. Salicylate Intoxication in an Infant: A Case Report. Drug Saf Case Rep. Nov 27 2017;4(1):23. doi:10.1007/s40800-017-0065-9 Goldberg MA, Barlow CF, Roth LJ. The effects of carbon dioxide on the entry and accumulation of drugs in the central nervous system. J Pharmacol Exp Ther. Mar 1961;131:308-18. Juurlink DN, Gosselin S, Kielstein JT, et al. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Ann Emerg Med. Aug 2015;66(2):165-81. doi:10.1016/j.annemergmed.2015.03.031 Kuzak N, Brubacher JR, Kennedy JR. Reversal of salicylate-induced euglycemic delirium with dextrose. Clin Toxicol (Phila). Jun-Aug 2007;45(5):526-9. doi:10.1080/15563650701365800 McCabe DJ, Lu JJ. The association of hemodialysis and survival in intubated salicylate-poisoned patients. Am J Emerg Med. Jun 2017;35(6):899-903. doi:10.1016/j.ajem.2017.04.017 Miyahara JT, Karler R. Effect of salicylate on oxidative phosphorylation and respiration of mitochondrial fragments. Biochem J. Oct 1965;97(1):194-8. doi:10.1042/bj0970194 Oliver TK, Jr., Dyer ME. The prompt treatment of salicylism with sodium bicarbonate. AMA J Dis Child. May 1960;99:553-65. doi:10.1001/archpedi.1960.02070030555001 Oualha M, Dupic L, Bastian C, Bergounioux J, Bodemer C, Lesage F. [Local salicylate transcutaneous absorption: an unrecognized risk of severe intoxication: a case report]. Arch Pediatr. Oct 2012;19(10):1089-92. Application cutanée localisée d'acide salicylique : un risque méconnu d'intoxication : à propos d'un cas. doi:10.1016/j.arcped.2012.07.012 Palmer BF, Clegg DJ. Salicylate Toxicity. N Engl J Med. Jun 25 2020;382(26):2544-2555. doi:10.1056/NEJMra2010852 Penniall R. The effects of salicylic acid on the respiratory activity of mitochondria. Biochim Biophys Acta. Nov 1958;30(2):247-51. doi:10.1016/0006-3002(58)90047-7 Shively RM, Hoffman RS, Manini AF. Acute salicylate poisoning: risk factors for severe outcome. Clin Toxicol (Phila). Mar 2017;55(3):175-180. doi:10.1080/15563650.2016.1271127 Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med. Sep 2008;15(9):866-9. doi:10.1111/j.1553-2712.2008.00205.x Thurston JH, Pollock PG, Warren SK, Jones EM. Reduced brain glucose with normal plasma glucose in salicylate poisoning. J Clin Invest. Nov 1970;49(11):2139-45. doi:10.1172/JCI106431 See omnystudio.com/listener for privacy information.

In this episode we explore ways in which the extracellular matrix can be manipulated, including the story of doxycycline, TGF-beta in Marfan syndrome and whether beta blockers can reduce vascular events in vascular EDS. ·        Intro 0:12 ·        Review of previous episode 0:28 ·        In this episode 2:26 ·        The pressure against the vessels 4:06 ·        The pressure against the wall 8:44 ·        Matrix metalloproteinases 10:16 ·        Tadpole study – collagen breakdown 10:35 ·        Tetracycline antibiotics 14:05 ·        Rat model – periodontal disease and hydroxyproline 14:24 ·        Chemically modified tetracyclines 20:14 ·        Mouse model – tetracycline use 22:00 ·        Tetracyclines and other autoimmune conditions 23:22 ·        Marfan syndrome 24:45 ·        Fibrillin and Marfan syndrome 28:48 ·        TGF-beta 29:36 ·        Mouse model – Marfan syndrome and fibrillin 31:14 ·        ARBs and TGF-beta 33:51 ·        TGF-beta and vascular EDS 37:25 ·        Back to the mouse model 38:38 ·        Protein kinase C 39:56 ·        Summary 40:26 Disclosures: Brown reports no relevant financial disclosures. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bowen CJ, et al. J Clin Invest. 2020;130:686-698. Brooke BS. Lancet. 2010;doi:10.1016/S0140-6736(10)61155-5 Dietz HC, et al. Am J Med Genet C Semin Med Genet. 2005;doi:10.1002/ajmg.c.30068. Dubacher N, et al. Cardiovasc Res. 2020;116:457-465. Golub LM, et al. SAGE. 1998;doi:10.1177/08959374980120010501. Gross J, et al. PNAS. 1962;doi:10.1073/pnas.48.6.1014 Habashi JP, et al. Science. 2006;312:117-121. Morissette R, et al. Circ Cardiovasc Genet. 2014;7:80-88. Mullen M, et al. Lancet. 2019;394:2263-2270. Neptune ER, et al. Nat Genet. 2003;33:407-411.

Dr Nally reviews the recent thyroid medication recall and discusses how protein and muscle maintenance plays a key role in weight loss. https://www.docmuscles.com/dietpage/ #LeadFolloworGetOutOrMyWay #JustKeepEsterifying #Ketogenic #Keto #KetogenicLifestyle #Carnivore #DrAdamNally #DocMuscles #DocMusclesLive #DocTalk #DocsWhoLift #LiftRunShoot #DocMusclesLife #PlantBasedDietsSuck #NoBSsm Show References: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ibsa-pharma-inc-issues-voluntary-nationwide-recall-select-lots-tirosintr-sol-levothyroxine-sodium Kiddy DS, Hamilton-Fairley D, Seppala M, Koistinen R, James VHT, Reed MJ, Franks S. DIET-INDUCED CHANGES IN SEX HORMONE BINDING GLOBULIN AND FREE TESTOSTERONE IN WOMEN WITH NORMAL OR POLYCYSTIC OVARIES: CORRELATION WITH SERUM INSULIN AND INSULIN-LIKE GROWTH FACTOR-I. Clin Endocrin. Dec 1989 https://doi.org/10.1111/j.1365-2265.1989.tb01297.x James N. Roemmich and Wayne E. Sinning. Weight loss and wrestling training: effects on growth-related hormones. Journal of Applied Physiology 1997 82:6, 1760-1764. Adeva-Andany MM, Funcasta-Calderón R, Fernández-Fernández C, Castro-Quintela E, Carneiro-Freire N. Metabolic effects of glucagon in humans. Journal of Clinical & Translational Endocrinology. 2019 Mar;15:45-53. DOI: 10.1016/j.jcte.2018.12.005. PMID: 30619718; PMCID: PMC6312800. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, Thorner MO. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988 Apr;81(4):968-75. doi: 10.1172/JCI113450. PMID: 3127426; PMCID: PMC329619. Møller N, Jørgensen JO, Abildgård N, Orskov L, Schmitz O, Christiansen JS. Effects of growth hormone on glucose metabolism. Horm Res. 1991;36 Suppl 1:32-5. PMID: 1806481. Antonio, J., Peacock, C.A., Ellerbroek, A. et al. The effects of consuming a high protein diet (4.4 g/kg/d) on body composition in resistance-trained individuals. J Int Soc Sports Nutr 11, 19 (2014). https://doi.org/10.1186/1550-2783-11-19 Longland TM, Oikawa SY, Mitchell CJ, Devries MC, Phillips SM. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. Am J Clin Nutr. 2016 Mar;103(3):738-46. doi: 10.3945/ajcn.115.119339. Epub 2016 Jan 27. PMID: 26817506. Jay R. Hoffman, Michael J. Falvo. (2004) Protein - Which is Best?. Journal of Sports Science and Medicine (03), 118 - 130. Fenzl M et al., Release of ANP and Fat Oxidation in Overweight Persons during Aerobic Exercise in Water. Int J Sports Med. Feb 2013. Vol 34. doi: 10.1055/s-0033-1333696

Confused about nutrition advice? First things first.. Don't let anyone tell you how to eat if you have found the gold standard that works for you.   Second thing… I see it every single day in practice. We are led astray with trendy nutrition advice that is not backed by science and is making us SICK.   Third thing.. I hate seeing friends and family confused about nutrition advice so I decided to make a podcast about it..   Thank you so much for joining me for this week's episode. This episode is for you if you want to hear all about how the keto diet was the worst thing I had ever done for my health and why fruit is your new bff!   FREE One Day Detox https://www.inspirehealthbyjen.com/onedaydetox   Blog https://www.middaypigeon.com/   Work with me: https://www.inspirehealthbyjen.com/work-with-jen   Podcast requests and questions:  https://forms.gle/bbpYJKTPhmsezYs3A   Work with Jen: https://www.inspirehealthbyjen.com/   If you have questions or would like me to help you get started… Let's get in touch and begin your true path of healing today. Your body and your mind will eternally thank you!   Keto blog: https://www.middaypigeon.com/complete-blog/how-the-keto-diet-wrecked-me?rq=keto    Fruit fear blog:  https://www.middaypigeon.com/complete-blog/fruit-fear   Hussain TA, Mathew TC, Dashti AA, Asfar S, Al-zaid N, Dashti HM. Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes. Nutrition. 2012;28(10):1016-21. Sweeney JS. Dietary factors that influence the dextrose tolerance test. JAMA. 1927;40(6):818-830. Himsworth HP. Dietetic factors influencing the glucose tolerance and the activity of insulin. J Physiol (Lond). 1934;81(1):29-48. Robertson MD, Henderson RA, Vist GE, Rumsey RD. Extended effects of evening meal carbohydrate-to-fat ratio on fasting and postprandial substrate metabolism. Am J Clin Nutr. 2002;75(3):505-10. Hernández EÁ, Kahl S, Seelig A, et al. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J Clin Invest. 2017;127(2):695-708. Angeloni C, Zambonin L, Hrelia S. Role of methylglyoxal in Alzheimer's disease. Biomed Res Int. 2014;2014:238485. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911-16.e12. Beisswenger BG, Delucia EM, Lapoint N, Sanford RJ, Beisswenger PJ. Ketosis leads to increased methylglyoxal production on the Atkins diet. Ann N Y Acad Sci. 2005;1043:201-10.

Glicemia ed Oscillazioni dell'Umore, ci sono fondamenti scientifici a supporto del fatto che alterazioni fisiologiche della glicemia possano influenzare l'umore di persone sensibili sul piano psichico e comportamentale a cambiamenti dei livelli di glucosio nel sangue?Ha un fondamento di verità il fatto che l'iperglicemia possa indurre fenomeni depressivi mentre l'ipoglicemia possa generare rabbia, irritabilità e disforia?Ecco alcuni studi clinici a supporto di quanto affermato nel video: (1) Anderson RJ. Freedland KE. Clouse RE. Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–1078. doi: 10.2337/diacare.24.6.1069 (2) Marcovecchio, ML. Chiarelli, F. The effects of acute and chronic stress on diabetes control. Sci Signal 5. 2012; 10. doi: 10.1126/scisignal.2003508 Atkinson FS. Foster-Poell K. Brand-Miller JC. Glycemic index (GI) and glycemic load (GL) values determined in subjects with normal glucose tolerance: 2008. Diabetes Care. 2008;31(12):2281-3. doi: 10.2337/dc08-1239 (2) Penckofer S, Quinn L, Byrn M, Ferrans C, Miller M, Strange P. Does glycemic variability impact mood and quality of life?. Diabetes Technol Ther. 2012;14(4):303–310. doi: 10.1089/dia.2011.0191 (3) Knüppel A, Shipley MJ, Llewellyn CH, Brunner EJ. Sugar intake from sweet food and beverages, common mental disorder and depression: prospective findings from the Whitehall II study. Sci Rep. 2017;7(1):6287. Published 2017 Jul 27. doi:10.1038/s41598-017-05649-7 (4) Gonder-Frederick LA. Cox DJ. Bobbit SA. Pennebaker JW. Mood changes associated with blood glucose fluctuations in insulin-dependent diabetes mellitus. Health Psychol. 1989;8:45–59. (5) Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777–781. doi:10.1172/JCI112884 #glicemia#umore #irritabilitàIl Dr. Valerio Rosso, su questo canale YouTube, si dedica a produrre delle brevi lezioni di psichiatria rivolte ai pazienti, agli operatori della salute mentale, ai famigliari dei pazienti, agli studenti di medicina, agli specializzandi in psichiatria e a chiunque sia interessato alla salute mentale, alla psichiatria ed alle neuroscienze.ISCRIVETEVI AL MIO CANALE ► https://bit.ly/2zGIJorVi interessano la Psichiatria e le Neuroscienze? Bene, allora iscrivetevi a questo canale YouTube e seguitemi sul web tramite il mio blog https://www.valeriorosso.comScoprite tutti i miei libri: https://bit.ly/2JdjocYScoprite la mia Musica: https://bit.ly/2JMqNjZVisitate anche il mio blog: https://www.valeriorosso.comAvete mai sentito parlare del progetto psiq? Andate subito ad informarvi su https://psiq.it ed iscrivetevi alla newsletter.

Listen in as Dr. Nally discussed the history of gout, why Hippocrates only thought it happened to royalty and how you can treat and prevent it with a ketogenic or carnivorous lifestyle. Show Note Sources: Kanbara A., Seyama I. Effect of urine pH on uric acid excretion by manipulating food materials. Nucleosides, Nucleotides Nucleic Acids. 2011;30(12):1066–1071. Towiwat P., Li Z.G. The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. Int J Rheum Dis. 2015;18(5):495–501. Bedir A., Topbas M., Tanyeri F., Alvur M., Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44(4):527–536. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout, 2nd ed, Walton and Maberly, London 1863. Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis 2018; 77:1048. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967; 42:27. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421. Zalokar J, Lellouch J, Claude JR, Kuntz D. Epidemiology of serum uric acid and gout in Frenchmen. J Chronic Dis 1974; 27:59. BRILL JM, MCCARTY DJ. "STUDIES ON THE NATURE OF GOUTY TOPHI" BY MAX FREUDWEILER, 1899. (AN INFLAMMATORY RESPONSE TO INJECTED SODIUM URATE, 1899). AN ABRIDGED TRANSLATION, WITH COMMENTS. Ann Intern Med 1964; 60:486. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54:452. Seegmiller JE, Howell RR, Malawista SE. The inflammatory reaction to sodium urate: its possible relationship to the genesis of acute gouty arthritis. JAMA 1962; 180:469. Hutton J, Fatima T, Major TJ, et al. Mediation analysis to understand genetic relationships between habitual coffee intake and gout. Arthritis Res Ther 2018; 20:135. Fanning N, Merriman TR, Dalbeth N, Stamp LK. An association of smoking with serum urate and gout: A health paradox. Semin Arthritis Rheum 2018; 47:825. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27:1045. Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006; 119:800.e13. Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33:1341. Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet Disord 2015; 16:296. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15:189. Horvath SM, Hollander JL. INTRA-ARTICULAR TEMPERATURE AS A MEASURE OF JOINT REACTION. J Clin Invest 1949; 28:469. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32:1443. Terkeltaub R, Zachariae C, Santoro D, et al. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991; 34:894. di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991; 87:1375. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32:1443.

How is the synovial fluid produced? Who figured it out? It's a ripping yarn involving corpses, cats, anti-hypertensives, steroids and streptococcus. Intro :11 Today's episode :15 Synovium 101 :22 Overview of the synovium and synovial fluid 2:06 How they figured it out? Dr. Marian Ropes 5:37 Investigating synovial fluid 7:46 Cows experiment and where synovial fluid comes from 11:25 Clinical review of synovial fluid 14:57 What's inside the fluid? 18:54 What makes up the fluid? 20:51 How do things get out of the synovium? 23:19 How are things absorbed into the synovium? 27:21 How well do steroids get picked up systemically? 29:39 Summary 32:30 Thank you 34:59 Disclosures: Brown reports no relevant financial disclosures. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Edwards JC. J Anat. 1994;184:493-501. Rhinelander FW, et al. J Clin Invest. 1939;doi:10.1172/JCI101011. Shaffer MF, et al. J Exp Med. 1939;doi:10.1084/jem.70.3.293. Stout A, et al. PM R. 2019;doi:10.1002/pmrj.12042.

The Team with Invincible Values discusses whether dogs or cats passively carry SARS-CoV-2 on hair and foot pads, maternal to fetal transfer of antibodies in infected or vaccinated pregnant women, and evidence that retroviruses infected cetaceans before and after they moved into the oceans. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, and Brianne Barker Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode SARS-CoV-2 on dogs and cats (Viruses) Maternal to neonatal transfer of SARS-CoV-2 antibodies (J Clin Investîmes) Retroviral evolution in cetaceans and their ancestors (Plos Path( Letters read on TWiV 781 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Current Map | U.S. Drought Monitor Brianne – A comic strip about immune responses Alan – Superliminal game Vincent – Birds are dying in NJ Listener Picks 2listening1 – Renewal Em – Cognitive Surplus Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

The Team with Invincible Values discusses whether dogs or cats passively carry SARS-CoV-2 on hair and foot pads, maternal to fetal transfer of antibodies in infected or vaccinated pregnant women, and evidence that retroviruses infected cetaceans before and after they moved into the oceans. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, and Brianne Barker Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode SARS-CoV-2 on dogs and cats (Viruses) Maternal to neonatal transfer of SARS-CoV-2 antibodies (J Clin Investîmes) Retroviral evolution in cetaceans and their ancestors (Plos Path( Letters read on TWiV 781 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Current Map | U.S. Drought Monitor Brianne – A comic strip about immune responses Alan – Superliminal game Vincent – Birds are dying in NJ Listener Picks 2listening1 – Renewal Em – Cognitive Surplus Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Episode 6: Our guest, Scott Cameron MD, PhD is a cardiology and vascular medicine specialist and is the Section Head of Vascular Medicine at Cleveland Clinic James Horowitz MD is a cardiac intensivist and is the director of the Cardiac ICU and NYU Langone Health.  Links:  The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Lefrançais E, et al. Nature. 2017. PMID: 28329764 https://pubmed.ncbi.nlm.nih.gov/28329764/ Lung megakaryocytes are immune modulatory cells.Pariser D, et al. J Clin Invest. 2021. PMID: 33079726https://pubmed.ncbi.nlm.nih.gov/33079726/ Megacaryocytes and platelet clumps as the cause of finger clubbing.Dickinson CJ, Martin JF. Lancet 1987. PMID: 2891996https://pubmed.ncbi.nlm.nih.gov/2891996/ Histopathologic analysis of extracted thrombi from deep venous thrombosis and pulmonary embolism: Mechanisms and timing. Silver MJ et al. Catheter Cardiovasc Interv 2021. PMID: 33522027https://pubmed.ncbi.nlm.nih.gov/2891996/

Pediatric intensivist Dr. Will Cagle joins the show to discuss the AAP Maintenance IV fluid guidelines and considerations when choosing IV fluids for pediatric inpatients. What do you need to know from the 2018 AAP maintenance IV fluid guideline?  How common is hyponatremia in hospitalized patients and why does it matter to your practice?  What is SIADH and how does it contribute to hyponatremia in acutely ill children?  How can we prevent hyponatremia in our hospitalized patients?  What are the differences between hypotonic and isotonic fluids?  What are balanced solutions and why might they be preferred as compared to saline in some clinical settings?  All of this and more from the Department of Pediatrics and the Medical College of Georgia.  Check out our website for detailed show-notes: https://www.augusta.edu/mcg/pediatrics/residency/podcast.php Special thanks to Dr. Asif Mansuri and Dr. Gene Fisher for providing peer review for this episode. Questions, comments, or feedback? Please email us at mcgpediatricpodcast@augusta.edu  Want Further Reading? Check out the clinical practice guideline from the AAP and our other references below. Feld LG,Neuspiel DR, Foster BA, et al. Clinical Practice Guideline: Maintenance Intravenous Fluids in Children. Pediatrics. 2018;142(6):e20183083. doi:10.1542/peds.2018-3083  Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in CriticallyIll Adults. N Engl J Med. 2018;378(9):829-839. doi:10.1056/NEJMoa1711584  CuzzoB, Padala SA, Lappin SL. Vasopressin (Antidiuretic Hormone, ADH) [Updated 2020 Apr 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526069/  Chowdhury, Abeed H. BSc, MRCS*; Cox, Eleanor F. PhD†; Francis, Susan T. PhD†; Lobo, Dileep N. DM, FRCS, FACS*A Randomized, Controlled, Double-Blind Crossover Study on the Effects of 2-L Infusions of 0.9% Saline and Plasma-Lyte® 148 on Renal Blood Flow Velocity and Renal Cortical Tissue Perfusion in Healthy Volunteers, Annals of Surgery: July 2012 - Volume 256 - Issue 1 - p 18-24 doi: 10.1097/SLA.0b013e318256be72  Peti-Peterdi J, Harris RC. Maculadensa sensing and signaling mechanisms of renin release. J Am Soc Nephrol. 2010;21(7):1093-1096. doi:10.1681/ASN.2009070759  Wilcox CS. Regulation of renal blood flow by plasma chloride.J Clin Invest. 1983;71(3):726-735. doi:10.1172/jci110820 

In this episode, we delve into Parvovirus B19: What does it do? How does it affect the joints? How was it discovered? Does it only infect young female schoolteachers? Find out! Brought to you by Actemra Intro :12 Shout out to Cleveland Clinic Biologic Therapies Summit 1:22 In this episode 2:11 An overview of the virus 3:46 What causes the aplastic crisis? 6:16 What does the virus do in humans? 11:46 A two-phase trial on young adults 14:29 A summary of studies 18:55 So, what happens to these patients? 22:59 How about a long-term study? 24:39 Summing up Parvovirus 19 26:42 The big takeaway from this episode 27:33 The next episode 28:06 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Anderson MJ, et al. J Infect Dis. 1985;152:257-265. Chorba T, et al. J Infect Dis. 1986;154:383-393. Moore TL. Curr Opin Rheumatol. 2000;12:289-294. Mortimer PP. Nature. 1983;302:426-429. Ogawa E, et al. J Infect Chemother. 2008;14:377-382. Potter CG. J Clin Invest. 1987;79:1486-1492. Reid DM, et al. Lancet. 1985;1:422-425. Speyer I, et al. Clin Exp Rheumatol. 1998;16:576-578. Takahashi Y, et al. Proc Natl Acad Sci USA. 1998;95:8227-8232. White DG, et al. Lancet. 1985;1:419-421. Young N, et al. J Clin Invest. 1984;74:2024-2032. Young NS, Brown KE. N Engl J Med. 2004;350:586-597.

What is this thing called pain? Woolf CJ. J Clin Invest. 2010 Nov;120(11):3742-4. doi: 10.1172/JCI45178. Epub 2010 Nov 1. PMID: 21041955 --- Send in a voice message: https://anchor.fm/moveman/message

This episode walks us through the initial research that paved the way for a game changing therapeutic in ANCA vasculitis, as well as the story of how host Adam J. Brown, MD, finally learned how to spell complement. Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com. Intro :10 Welcome :21 Today’s episode :24 So how did we get there? 4:18 How do we start teasing apart the effect of the complement in ANCA vasculitis? 8:13 Discussing and simplifying the mouse model 9:00 Quickly reviewing the complement cascade 12:06 Brought to you by GSK. Consider the long-term impact of disease activity flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com. Taking the puzzle pieces away in the mouse model 17:04 What about the next steps? 22:05 What happens when you block C5a? 25:12 CCX168: Summing up the mouse tale 28:44 In the next episode 30:20 Thanks for listening 30:46 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Brilland B, et al. Autoimmun Rev. 2020;19:102424. Freeley SJ, et al. J Pathol 2016;240:61-71. Haas M, Eustace JA. Kidney Int 2004;65:2145-2152. Huugen D, et al. Kidney Int 2007;71:646-654. Marder SR, et al. Arg. J Immunol. 1985;134:3325-3331. Schreiber A, et al. J Am Soc Nephrol. 2009;20:289-298. Xiao H, et al. Am J Pathol. 2007;170:52-64. Xiao H, et al. J Clin Invest 2002;110:955–963. Xiao H, et al. J Am Soc Nephrol, 2014;25:225–231.

In this episode, Dr. Scott and Tommy dive into the history of the last 100 years since the discovery of insulin. Medical and technological breakthroughs are oftentimes significant inflection points for society, but not always in the positive ways they're expected to be. They discuss where we came from, the state of the union of society's health, where we're headed, as well as how to accelerate positive change.   Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom. Belinda S. Lennerz,1,2,3 Andrew P. Koutnik,4,5 Svetlana Azova,1,2,3 Joseph I. Wolfsdorf,2,3 and David S. Ludwig1,2,3. J Clin Invest. 2021;131(1):e142246.https://doi.org/10.1172/JCI142246.   Have a question you'd like us to answer? Click here to send it to us or leave us a voicemail we can play on the show!   Show Transcript: www.thefastingforlife.com/blog   If you enjoy the podcast, would you please tap on the stars below and consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a difference in helping to bring you the best original content each week. We also just enjoy reading them!   Sign up for the Fasting For Life newsletter at www.thefastingforlife.com   Join the Community on Facebook!   Follow Fasting For Life: www.facebook.com/thefastingforlife www.instagram.com/thefastingforlife

The completion of the Endocarditis for the Rheumatologist trilogy! This episode focuses on the glomerulonephritis of endocarditis as well as the immunologic abnormalities you can see on labs. Brought to you by GSK. Consider the long-term impact of disease activity flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com. Intro :11 In this episode :22 Recap of previous episodes :39 About episode three 1:00 How labs can give a clue to endocarditis being a culprit 1:23 The immune complex nature of infective endocarditis 6:30 How do you measure immune complex? 9:10 What are the effects of immune complex formation on the organ systems? 12:37 Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com. Cryoglobulins and rheumatoid factor in infective endocarditis 15:12 The kidneys and infective endocarditis 16:45 Glomerulonephritis and infective endocarditis 24:15 ANCA-positive vasculitis and infective endocarditis 29:09 A summary of infective endocarditis 32:21 Takeaways 33:28 A preview of next episode 33:48 Conclusion 34:12 Disclosure: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Bayer AS, et al. N Engl J Med. 1976;295:1500-1505. Boils CL, et al. Kidney Int. 2015;87:1241-1249. Forte WC, et al. Arq Bras Cardiol. 2001;76:43-52. Hurwitz D, et al. Clin Exp Immunol. 1975;19:131-141. Langlois V, et al. Medicine (Baltimore). 2016;95:e2564. Levy RL, Hong R. Am J Med. 1973;54:645-652. Ma T-T, et al. PLoS One. 2014;9: https://doi.org/10.1371/journal.pone.0097843. Messias-Reason IL, et al. Clin Exp Immunol. 2002;127:310-315. Petersdorf RG. N Engl J Med. 1976;295:1534-1535. Spain DM, King DW. Ann Intern Med. 1952;36:1086-1089. Williams Jr RC, Kunkel HG. J Clin Invest. 1962;41:666-675. Tire squealing sound effect by Mike Koenig.

Pediatric intensivist, Dr. Will Cagle joins the show to discuss the AAP Maintenance IV fluid guidelines and considerations when choosing IV fluids for pediatric inpatients. What do you need to know from the 2018 AAP maintenance IV fluid guideline?  How common is hyponatremia in hospitalized patients and why does it matter to your practice?  What is SIADH and how does it contribute to hyponatremia in acutely ill children?  How can we prevent hyponatremia in our hospitalized patients?  What are the differences between hypotonic and isotonic fluids?  What are balanced solutions and why might they be preferred as compared to saline in some clinical settings?  All of this and more from the Department of Pediatrics and the Medical College of Georgia.  Check out our website for detailed show-notes: https://www.augusta.edu/mcg/pediatrics/residency/podcast.php Special thanks to Dr. Asif Mansuri and Dr. Gene Fisher for providing peer review for this episode. Questions, comments, or feedback? Please email us at mcgpediatricpodcast@augusta.edu  Want Further Reading? Check out the clinical practice guideline from the AAP and our other references below. Feld LG, Neuspiel DR, Foster BA, et al. Clinical Practice Guideline: Maintenance Intravenous Fluids in Children. Pediatrics. 2018;142(6):e20183083. doi:10.1542/peds.2018-3083  Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018;378(9):829-839. doi:10.1056/NEJMoa1711584  Cuzzo B, Padala SA, Lappin SL. Vasopressin (Antidiuretic Hormone, ADH) [Updated 2020 Apr 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526069/  Chowdhury, Abeed H. BSc, MRCS*; Cox, Eleanor F. PhD†; Francis, Susan T. PhD†; Lobo, Dileep N. DM, FRCS, FACS* A Randomized, Controlled, Double-Blind Crossover Study on the Effects of 2-L Infusions of 0.9% Saline and Plasma-Lyte® 148 on Renal Blood Flow Velocity and Renal Cortical Tissue Perfusion in Healthy Volunteers, Annals of Surgery: July 2012 - Volume 256 - Issue 1 - p 18-24 doi: 10.1097/SLA.0b013e318256be72  Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol. 2010;21(7):1093-1096. doi:10.1681/ASN.2009070759  Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Invest. 1983;71(3):726-735. doi:10.1172/jci110820 

Episode 347 is an updated guide to somatropic hormone and GOD did I go crazy on this one! I honestly want to know more about growth hormone than anyone alive and thus, begins this string of GH based guides! I DID finally discuss the MoA for how GH causes localized fat loss which really had me excited since no one in our industry has EVER talked about this so that definitely was an interesting avenue to go down! Below I am going to reference a lot of the literature for this hormone that I was read through over the past few years on this topic so please DO NOT TAKE MY WORD FOR THIS - READ THESE YOURSELF! Keep in mind this is a brief snippet of every bit of literature on the topic however. REFERENCES   Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989;10:68–91. [PubMed] [Google Scholar] Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3–34. [PubMed] [Google Scholar] Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22:53–74. [PubMed] [Google Scholar] Melmed S. Endocrinology. 5th edn. Philadelphia: Elsevier Saunders; 2006. pp. 411–428. [Google Scholar] Fain, J. N., García‐Sáinz, JA. (1983) Adrenergic regulation of adipocytes metabolism. J Lipid Res 24: 945– 966. CAS PubMed Web of Science®Google Scholar  Gilman, AG. (1987) G protein: transducer of receptor‐generated signals. Annu Rev Biochem 56: 615– 649. Crossref CAS PubMed Web of Science®Google Scholar  Jimenez, M., Lèger, B., Canola, K., et al (2002) Beta(1)/beta(2)/beta(3)‐adrenoceptor knockout mice are obese and cold‐sensitive but have normal lipolytic responses to fasting. FEBS Lett 530: 37– 40. Wiley Online Library CAS PubMed Web of Science®Google Scholar  Birnbaumer, L., Abramowitz, J., Brown, AM. (1990) Receptor‐effector coupling by G proteins. Biochim Biophys Acta 1031: 163– 224. Crossref CAS PubMed Web of Science®Google Scholar  Spiegel, A. M., Shenker, A., Weinstein, LS. (1992) Receptor‐effector coupling by G‐protein: implications for normal and abnormal signal transduction. Endocr Rev 13: 536– 565. Crossref CAS PubMed Web of Science®Google Scholar  Beebe, S. J., Holloway, R., Rannels, R. S., Corbin, JD. (1984) Two classes of cAMP analogs which are selective for the two different cAMP‐binding sites of type II protein kinase demonstrate synergism when added together to intact adipocytes. J Biol Chem 269: 3539– 3547. PubMed Google Scholar Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48–58. [PubMed] [Google Scholar] Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science. 2003;299:1346–1351. [PubMed] [Google Scholar] Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res. 2004;14:261–269. [PubMed] [Google Scholar] Laban C, Bustin SA, Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab. 2003;14:28–34. [PubMed] [Google Scholar] Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928. [PubMed] [Google Scholar] Mayo KE. A little lesson in growth regulation. Nat Genet. 1996;12:8–9. [PubMed] [Google Scholar] Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev. 1994;15:369–390. [PubMed] [Google Scholar] Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995;333:1093–1098. [PubMed] [Google Scholar] Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfaffle R, Raile K, Seidel B, Smith RJ, Chernausek SD. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003;349:2211–2222. [PubMed] [Google Scholar] Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996;335:1363–1367. [PubMed] [Google Scholar] Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001;229:141–162. [PubMed] [Google Scholar] Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA. IGF-I is required for normal embryonic growth in mice. Genes Dev. 1993;7:2609–2617. [PubMed] [Google Scholar] Sotiropoulos A, Ohanna M, Kedzia C, Menon RK, Kopchick JJ, Kelly PA, Pende M. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proc Natl Acad Sci U S A. 2006;103:7315–7320. [PMC free article] [PubMed] [Google Scholar] Fernandez AM, Dupont J, Farrar RP, Lee S, Stannard B, Le Roith D. Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest. 2002;109:347–355. [PMC free article] [PubMed] [Google Scholar] Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem. 1995;270:12109–12116. [PubMed] [Google Scholar] Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A. 1998;95:15603–15607. [PMC free article] [PubMed] [Google Scholar] Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3:1014–1019. [PubMed] [Google Scholar] Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195–200. [PubMed] [Google Scholar] Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157:137– 148. [PMC free article] [PubMed] [Google Scholar] Caroni P, Schneider C. Signaling by insulin-like growth factors in paralyzed skeletal muscle: rapid induction of IGF1 expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4. J Neurosci. 1994;14:3378–3388. [PMC free article] [PubMed] [Google Scholar] Edwall D, Schalling M, Jennische E, Norstedt G. Induction of insulin-like growth factor I messenger ribonucleic acid during regeneration of rat skeletal muscle. Endocrinology. 1989;124:820–825. [PubMed] [Google Scholar] DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am J Physiol. 1990;259:E89–E95. [PubMed] [Google Scholar] Carson JA, Nettleton D, Reecy JM. Differential gene expression in the rat soleus muscle during early work overload-induced hypertrophy. FASEB J. 2002;16:207–209. [PubMed] [Google Scholar] Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. New insights into growth hormone action. J Mol Endocrinol. 2006;36:1–7. [PubMed] [Google Scholar] Herrington J, Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab. 2001;12:252–257. [PubMed] [Google Scholar] Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2006;7:225–235. [PubMed] [Google Scholar] Rotwein P, Thomas MJ, Harris DM, Gronowski AM, LeStunff C. Nuclear actions of growth hormone: an in vivo perspective. J Anim Sci. 1997;75:11–19. [Google Scholar] Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene. 2000;19:2585–2597. [PubMed] [Google Scholar] Levy DE, Darnell JEJ. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651–662. [PubMed] [Google Scholar] Gronowski AM, Rotwein P. Rapid changes in nuclear protein tyrosine phosphorylation after growth hormone treatment in vivo. Identification of phosphorylated mitogen-activated protein kinase and STAT91. J Biol Chem. 1994;269:7874–7878. [PubMed] [Google Scholar] Gronowski AM, Zhong Z, Wen Z, Thomas MJ, Darnell JEJ, Rotwein P. In vivo growth hormone treatment rapidly stimulates the tyrosine phosphorylation and activation of Stat3. Mol Endocrinol. 1995;9:171–177. [PubMed] [Google Scholar] Ram PA, Park SH, Choi HK, Waxman DJ. Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation. J Biol Chem. 1996;271:5929–5940. [PubMed] [Google Scholar] Campbell GS, Meyer DJ, Raz R, Levy DE, Schwartz J, Carter-Su C. Activation of acute phase response factor (APRF)/Stat3 transcription factor by growth hormone. J Biol Chem. 1995;270:3974–3979. [PubMed] [Google Scholar] Smit LS, Vanderkuur JA, Stimage A, Han Y, Luo G, Yu-Lee LY, Schwartz J, Carter-Su C. Growth hormone-induced tyrosyl phosphorylation and deoxyribonucleic acid binding activity of Stat5A and Stat5B. Endocrinology. 1997;138:3426–3434. [PubMed] [Google Scholar] Smit LS, Meyer DJ, Billestrup N, Norstedt G, Schwartz J, Carter-Su C. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Mol Endocrinol. 1996;10:519–533. [PubMed] [Google Scholar] Gebert CA, Park SH, Waxman DJ. Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. Mol Endocrinol. 1997;11:400–414. [PubMed] [Google Scholar] Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841–850. [PubMed] [Google Scholar] Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A. 1997;94:7239–7244. [PMC free article] [PubMed] [Google Scholar] Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A, Heinrich JJ, Rosenfeld RG. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349:1139–1147. [PubMed] [Google Scholar] Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M, Rosenfeld RG. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab. 2005;90:4260–4266. [PubMed] [Google Scholar] Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V. Defects in growth hormone receptor signaling. Trends Endocrinol Metab. 2007;18:134–141. [PubMed] [Google Scholar] Thompson BJ, Shang CA, Waters MJ. Identification of genes induced by growth hormone in rat liver using cDNA arrays. Endocrinology. 2000;141:4321–4324. [PubMed] [Google Scholar] Flores-Morales A, Stahlberg N, Tollet-Egnell P, Lundeberg J, Malek RL, Quackenbush J, Lee NH, Norstedt G. Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology. 2001;142:3163–3176. [PubMed] [Google Scholar] Rowland JE, Lichanska AM, Kerr LM, White M, d'Aniello EM, Maher SL, Brown R, Teasdale RD, Noakes PG, Waters MJ. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol. 2005;25:66–77. [PMC free article] [PubMed] [Google Scholar] Huo JS, McEachin RC, Cui TX, Duggal NK, Hai T, States DJ, Schwartz J. Profiles of growth hormone (GH)-regulated genes reveal time-dependent responses and identify a mechanism for regulation of activating transcription factor 3 by GH. J Biol Chem. 2006;281:4132–4141. [PubMed] [Google Scholar] Vidal OM, Merino R, Rico-Bautista E, Fernandez-Perez L, Chia DJ, Woelfle J, Ono M, Lenhard B, Norstedt G, Rotwein P, Flores-Morales A. In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol Endocrinol. 2007;21:293–311. [PubMed] [Google Scholar] Clodfelter KH, Holloway MG, Hodor P, Park SH, Ray WJ, Waxman DJ. Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol. 2006;20:1333–1351. [PubMed] [Google Scholar] Jorgensen JO, Jessen N, Pedersen SB, Vestergaard E, Gormsen L, Lund SA, Billestrup N. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am J Physiol Endocrinol Metab. 2006;291:E899–E905. [PubMed] [Google Scholar] Nielsen C, Gormsen LC, Jessen N, Pedersen SB, Moller N, Lund S, Jorgensen JO. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J Clin Endocrinol Metab. 2008;93:2842–2850. [PubMed] [Google Scholar] Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006;20:2613–2629. [PubMed] [Google Scholar] Wauthier V, Waxman DJ. Sex-specific early growth hormone response genes in rat liver. Mol Endocrinol. 2008;22:1962–1974. [PMC free article] [PubMed] [Google Scholar] Ahluwalia A, Clodfelter KH, Waxman DJ. Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis. Mol Endocrinol. 2004;18:747–760. [PubMed] [Google Scholar] Zhou YC, Waxman DJ. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of pparalpha transcriptional activity mediated by stat5b. J Biol Chem. 1999;274:2672–2681. [PubMed] [Google Scholar] Zhou YC, Waxman DJ. STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 transactivation domain. J Biol Chem. 1999;274:29874–29882. [PubMed] [Google Scholar] Ono M, Chia DJ, Merino-Martinez R, Flores-Morales A, Unterman TG, Rotwein P. Signal transducer and activator of transcription (Stat) 5b-mediated inhibition of insulin-like growth factor binding protein-1 gene transcription: a mechanism for repression of gene expression by growth hormone. Mol Endocrinol. 2007;21:1443–1457. [PubMed] [Google Scholar] Murphy LJ. Insulin-like growth factor-binding proteins: functional diversity or redundancy? J Mol Endocrinol. 1998;21:97–107. [PubMed] [Google Scholar] Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab. 2005;16:183–189. [PubMed] [Google Scholar] Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117:421–426. [PubMed] [Google Scholar] Rotwein P. Contemporary endocrinology: the IGF system. Totowa: Humana Press; 1999. Molecular biology of IGF-I and IGF-II; pp. 19–35. [Google Scholar] Hall LJ, Kajimoto Y, Bichell D, Kim SW, James PL, Counts D, Nixon LJ, Tobin G, Rotwein P. Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter. DNA Cell Biol. 1992;11:301–313. [PubMed] [Google Scholar] Adamo ML, Ben-Hur H, Roberts CTJ, LeRoith D. Regulation of start site usage in the leader exons of the rat insulin-like growth factor-I gene by development, fasting, and diabetes. Mol Endocrinol. 1991;5:1677–1686. [PubMed] [Google Scholar] Shimatsu A, Rotwein P. Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor I gene. J Biol Chem. 1987;262:7894–7900. [PubMed] [Google Scholar] Kim SW, Lajara R, Rotwein P. Structure and function of a human insulin-like growth factor-I gene promoter. Mol Endocrinol. 1991;5:1964–1972. [PubMed] [Google Scholar] Kavsan VM, Koval AP, Grebenjuk VA, Chan SJ, Steiner DF, Roberts CTJ, LeRoith D. Structure of the chum salmon insulin-like growth factor I gene. DNA Cell Biol. 1993;12:729–737. [PubMed] [Google Scholar] Hoyt EC, Van Wyk JJ, Lund PK. Tissue and development specific regulation of a complex family of rat insulin-like growth factor I messenger ribonucleic acids. Mol Endocrinol. 1988;2:1077–1086. [PubMed] [Google Scholar] Woelfle J, Billiard J, Rotwein P. Acute control of insulin-like growth factor-1 gene transcription by growth hormone through STAT5B. J Biol Chem. 2003;278:22696–22702. [PubMed] [Google Scholar] Woelfle J, Chia DJ, Rotwein P. Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem. 2003;278:51261–51266. [PubMed] [Google Scholar] Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol. 1992;6:1899–1908. [PubMed] [Google Scholar] Thomas MJ, Kikuchi K, Bichell DP, Rotwein P. Characterization of deoxyribonucleic acid-protein interactions at a growth hormone-inducible nuclease hypersensitive site in the rat insulin-like growth factor-I gene. Endocrinology. 1995;136:562–569. [PubMed] [Google Scholar] An MR, Lowe WLJ. The major promoter of the rat insulin-like growth factor-I gene binds a protein complex that is required for basal expression. Mol Cell Endocrinol. 1995;114:77–89. [PubMed] [Google Scholar] Mittanck DW, Kim SW, Rotwein P. Essential promoter elements are located within the 5' untranslated region of human insulin-like growth factor-I exon I. Mol Cell Endocrinol. 1997;126:153–163. [PubMed] [Google Scholar] Wang L,Wang X, Adamo ML. Two putative GATA motifs in the proximal exon 1 promoter of the rat insulin-like growth factor I gene regulate basal promoter activity. Endocrinology. 2000;141:1118–1126. [PubMed] [Google Scholar] Wang X, Talamantez JL, Adamo ML. A CACCC box in the proximal exon 2 promoter of the rat insulin-like growth factor I gene is required for basal promoter activity. Endocrinology. 1998;139:1054–1066. [PubMed] [Google Scholar] Wang Y, Jiang H. Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression. J Biol Chem. 2005;280:10955–10963. [PubMed] [Google Scholar] Chia DJ, Ono M, Woelfle J, Schlesinger-Massart M, Jiang H, Rotwein P. Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription. J Biol Chem. 2006;281:3190–3197. [PubMed] [Google Scholar] Eleswarapu S, Gu Z, Jiang H. Growth hormone regulation of insulin-like growth factor-I gene expression may be mediated by multiple distal signal transducer and activator of transcription 5 binding sites. Endocrinology. 2008;149:2230–2240. [PMC free article] [PubMed] [Google Scholar] Björntorp, P. (1992) Biochemistry of obesity in relation to diabetes. In: KGMM Alberti RA DeFronzo H Keen P Zimmet eds. International Textbook of Diabetes Mellitus 551– 568. John Wiley & Sons Ltd London, United Kingdom. Google Scholar  Björntorp, P. (1992) Hormonal effects on fat distribution and its relationship to health risk factors. Acta Paediatr Suppl 383: 59– 60. CAS PubMed Google Scholar  Rosèn, T., Bosaeus, I., Tolli, J., Lindstedt, G., Bengtsson, BA. (1993) Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 38: 63 Wiley Online Library PubMed Web of Science®Google Scholar  Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) Cell. 1993;75:59–72. [PubMed] [Google Scholar] Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse) Proc Natl Acad Sci U S A. 1997;94:13215–13220. [PMC free article] [PubMed] [Google Scholar] Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000;106:1095–1103. [PMC free article] [PubMed] [Google Scholar] Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110:771–781. [PMC free article] [PubMed] [Google Scholar] Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001;142:4349–4356. [PubMed] [Google Scholar] Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441. [PubMed] [Google Scholar] Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest. 1997;99:2961–2970. [PMC free article] [PubMed] [Google Scholar] McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology. 1989;124:1247–1253. [PubMed] [Google Scholar] Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000;141:2674–2682. [PubMed] [Google Scholar] Bengtsson, BÅ, Edén, S., Lönn, L., et al (1993) Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76: 309– 317. Crossref CAS PubMed Web of Science®Google Scholar  Al‐Shoumer, K. A. S., Page, B., Thomas, E., Murphy, M., Beshyah, S. A., Johnston, DG. (1996) Effects of four years’ treatment with biosynthetic human growth hormone (GH) on body composition in GH‐deficient hypopituitary adults. Eur Endocrinol 135: 559– 567. Crossref CAS PubMed Web of Science®Google Scholar  Li, C. H., Simpson, M. E., Evans, HM. (1949) Influence of growth and adrenocorticotropic hormone on the body composition of hypophysectomized rats. Endocrinology 44: 71– 75. Crossref CAS PubMed Web of Science®Google Scholar  Scow, RO. (1959) Effects of growth hormone and thyroxine on growth and chemical composition of muscle, bone and other tissues in thyroidectomized‐hypophysectomized rats. Am J Physiol 196: 859– 865. CAS PubMed Web of Science®Google Scholar  Lee, M. O., Schaffer, NK. (1934) Anterior pituitary growth hormone and the composition of growth. J Nutr 7: 337– 363. Crossref CAS Web of Science®Google Scholar  Goodman, H. M., Schwartz, J. (1974) Growth hormone and lipid metabolism. In: E Enobil WH Sawyer eds. Handbook of Physiology, Part 2 IV: 211– 232. American Physiological Society Washington DC. Google Scholar  Bengtsson, BÅ, Brummer, R. J. M., Edén, S., Rosèn, T., Sjöström, L. (1992) Effects of growth hormone on fat mass and fat distribution. Acta Paediatr Suppl 383: 62– 65. PubMed Google Scholar  Tanner, J. M., Hughes, P. C. R., Whitehouse, RH. (1977) Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency. Acta Endocrinol (Copenh) 84: 53– 57. Google Scholar  Goodman, H. M., Gorin, E., Honeyman, TW. (1988) Biochemical basis for the lipolytic activity of growth hormone. In: LE Underwood eds. Human Growth Hormone: Progress and Challenges 75– 111. Marcel Dekker Inc New York. Google Scholar  Bonnet, F., Vanderschueren‐Lodeweyckx, M., Echels, R., Malvaux, P. (1974) Subcutaneous adipose tissue and lipids in blood in growth hormone deficiency before and after treatment with human growth hormone. Pediatr Res 8: 800– 805. Crossref CAS PubMed Web of Science®Google Scholar  van Vliet, G, Bosson, D., Craen, M., Caju, NVLD, Malvaux, P., Vanderschueren‐Lodeweyckx, M. (1987) Comparative study of the lipolytic potencies of pituitary‐derived and biosynthetic human growth hormone in hypopituitary children. J Clin Endocrinol Metab 65: 876– 879. Crossref PubMed Web of Science®Google Scholar  Beauville, M., Harent, I., Crampes, F., Riviere, D., Tauber, M. T., Tauber, J. P., Garrigues, M. (1992) Effect of long‐term rhGH administration in GH‐deficient adults on fat cell epinephrine response. Am J Physiol 263: E467– E472. Crossref CAS PubMed Web of Science®Google Scholar  Vernon, R. G., Flint, DJ. (1989) Role of growth hormone in the regulation of adipocyte growth and function. In: RB Heap, C Prosser GE Lamming eds. Biotechnology in Growth Regulation 57– 71. Butterworths London, United Kingdom. Crossref Web of Science®Google Scholar  Harant, I., Beauville, M., Crampes, F., et al (1994) Response of fat cells to growth hormone (GH): effect of long term treatment with recombinant human GH in GH‐deficient adults. J Clin Endocrinol Metab 78: 1392– 1395. Crossref PubMed Web of Science®Google Scholar  Marcus, C., Bolme, P., Micha‐Johansson, G., Margery, V., Brönnegård, M. (1994) Growth hormone increases the lipolytic sensitivity from catecholamines in adipocytes from healthy adults. Life Sci 54: 1335– 1341. Crossref CAS PubMed Web of Science®Google Scholar  Yang, S., Björntorp, P., Liu, X., Edén, S. (1996) Growth hormone treatment of hypophysectomized rats increases catecholamine‐induced lipolysis and the number of β‐adrenergic receptors in adipocytes: no differences in the effects of growth hormone on different fat depots. Obes Res 4: 471– 478. Wiley Online Library CAS PubMed Web of Science®Google Scholar  Watt, P. W., Finley, E., Cork, S., Legg, R. A., Vernon, RG. (1991) Chronic control of the β‐ and α2‐adrenergic systems of sheep adipose tissue by growth hormone and insulin. Biochem J 273: 39– 42. Crossref CAS PubMed Web of Science®Google Scholar  Arner, P. (1992) Adrenergic receptor function in fat cells. Am J Clin Nutr 55: 228S– 236S. Crossref CAS PubMed Web of Science®Google Scholar  Arner, P., Hellmér, J., Wennlund, A., Östman, J., Engfeldt, P. (1988) Adrenoceptor occupancy in isolated human fat cells and its relationship with lipolysis rate. Eur J Pharmacol 146: 45– 56. Crossref CAS PubMed Web of Science®Google Scholar  Davidson, MB. (1987) Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8: 115– 131. Crossref CAS PubMed Web of Science®Google Scholar  Ottosson, M., Lönnroth, P., Björntorp, Edén S. (2000) Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J Clin Endocrinol Metab 85: 799– 803. Crossref CAS PubMed Web of Science®Google Scholar  Pierlussi, J., Pierlussi, R., Aschcroft, SJH. (1980) Effects of growth hormone on insulin release in the rat. Diabetologia 19: 391– 396. Crossref PubMed Web of Science®Google Scholar  Roupas, P., Ghou, S. T., Towns, R. J., Kostyo, JL. (1991) Growth hormone inhibits activation of phosphatidylinositol phospholipase C in adipose plasma membranes: evidence for a growth hormone‐induced change in G protein function. Physiol Pharmacol 88: 1691– 1695. CAS PubMed Web of Science®Google Scholar  72 Slavin, B. G., Ong, J. M., Kern, P. (1994) Hormonal regulation of hormone‐sensitive lipase activity and mRNA levels in isolated rat adiposities. J Lipid Res 35: 1535– 1541. CAS PubMed Web of Science®Google Scholar  Sheridan, MK. (1986) Effects of thyroxin, cortisol, growth hormone, and prolactin on lipid metabolism of coho salmon, oncorhynchus kisutch, during smoltification. Gen Comp Endocrinol 64: 220– 238. Crossref CAS PubMed Web of Science®Google Scholar  Dietz, J., Schwartz, J. (1991) Microdetermination of long chain fatty acids in plasma and tissue. J Biol Chem 235: 2595– 2599. PubMed Web of Science®Google Scholar Yang, S., Xu, X., Björntorp, P., Edén, S. (1995) Additive effects of growth hormone and testosterone on lipolysis in adipocytes of hypophysectomized rats. J Endocrinol 147: 147– 152. Crossref CAS PubMed Web of Science®Google Scholar  Lands, A. M., Arnold, A., McAuliff, J. P., Bron, TG. (1967) Differentiation of receptor systems activated by sympathetic amines. Nature 214: 597– 598. Crossref CAS PubMed Web of Science®Google Scholar  Stiles, G. L., Caron, M. G., Lefkowitz, RJ. (1984) β‐Adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev 64: 661– 743. Crossref CAS PubMed Web of Science®Google Scholar  Emorine, L. J., Marullo, S., Briend‐Sutren, M. M., et al (1989) Molecular characterization of human β3‐adrenergic receptor. Science 245: 1118– 1121. Crossref CAS PubMed Web of Science®Google Scholar  Ahquist, RP. (1948) A study of the adrenotropic receptors. Am J Physiol 153: 586– 600. PubMed Web of Science®Google Scholar  Honnor, R. C., Dhillon, G. S., Londos, C. (1985) cAMP‐dependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation and predictability in behavior. J Biol Chem 260: 15122– 15129. CAS PubMed Web of Science®Google Scholar  Honnor, R. C., Dhillon, G. S., Londos, C. (1985) cAMP‐dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady‐state relationship with lipolytic and antilipolytic modulators. J Biol Chem 260: 15130– 15138. CAS PubMed Web of Science®Google Scholar  Corbin, J. D., Cobb, C. E., Beebe, S. J., et al (1988) Mechanism and function of cAMP‐ and cGMP‐dependent protein kinases. Adv Second Messenger Phosphoprotein Res 21: 75– 86. CAS PubMed Web of Science®Google Scholar  Londos, C., Brasaemle, D. L., Schultz, C. J., Segrest, J. P., Kimmel, AR. (1999) Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin Cell Dev Biol 10: 51– 58. Crossref CAS PubMed Web of Science®Google Scholar  Holm, C., Osterlund, T., Laurell, H., Contreras, JA. (2000) Molecular mechanisms regulating hormone‐sensitive lipase and lipolysis. Annu Rev Nutr 20: 365– 393. Crossref CAS PubMed Web of Science®Google Scholar  Brasaemle, D. L., Rubin, B., Harten, I. A., Gruia‐Gray, J., Kimmel, A. R., Londos, C. (2000) Perilipin A increases triacylglycerol storage by decreasing the rate of triacylglycerol hydrolysis. J Biol Chem 275: 38486– 38493. Crossref CAS PubMed Web of Science®Google Scholar  Tansey, J. T., Huml, A. M., Vogt, R., et al (2003) Functional studies on native and mutated forms of perilipins. A role in protein kinase A‐mediated lipolysis of triacylglycerols. J Biol Chem 278: 8401– 8406. Crossref CAS PubMed Web of Science®Google Scholar  Strålfors, P., Björgell, P., Belfrage, P. (1984) Hormone regulation of hormone‐sensitive lipase in intact adipocytes: Identification of phosphorylated sites and effects of the phosphorylation by lipolytic hormone and insulin. Proc Natl Acad Sci U S A 81: 3317– 3321. Crossref CAS PubMed Web of Science®Google Scholar  Egan, J. J., Greenberg, A. S., Chang, M. K., Wek, SA Moos JMC, Londos, C. (1992) Mechanism of hormone‐stimulated lipolysis in adipocytes: translocation of hormone‐sensitive lipase to the lipid storage droplet. Proc Natl Acad Sci U S A 89: 8537– 8541. Crossref CAS PubMed Web of Science®Google Scholar  Anthonsen, M. W., Ronnstrand, L., Wernstedt, C., Degerman, E., Holm, C. (1998) Identification of novel phosphorylation sites in hormone‐sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem 273: 215– 221. Crossref CAS PubMed Web of Science®Google Scholar  Sztalryd, C., Xu, G., Dorward, H., et al (2003) Perilipin A is essential for the translocation of hormone‐sensitive lipase during lipolytic activation. J Cell Boil 161: 1093– 1103. Crossref CAS PubMed Web of Science®Google Scholar  Smith, PE. (1930) Hypophysectomy and replacement therapy in the rat. Am J Anat 45: 205– 273. Wiley Online Library Web of Science®Google Scholar  Edén, S., Jansson, J. O., Oscarsson, J. (1987) Sexual dimorphism of growth hormone secretion. In: O Isaksson C Binder K Hall B Hökfelt eds. Growth Hormone—Basic and Clinical Aspects 129– 151. Elsevier Science Publishers B.V Amsterdam. Google Scholar  Frohman, L. A., Bernardis, LL. (1970) Growth hormone secretion in rat: metabolic clearance and secretion rates. Endocrinology 86: 305– 312. Crossref CAS PubMed Google Scholar  Jansson, J. O., Albertsson‐Wikaland, K., Edén, S., Thorngren, K. G., Isaksson, O. (1982) Circumstantial evidence for a role of the secretory pattern of growth hormone in control of body growth. Acta Endocrinol 99: 24– 30. CAS PubMed Web of Science®Google Scholar  Björntorp, P., Karlsson, M., Pertoft, H., Pettersson, P., Sjöström, L., Smith, U. (1978) Isolation and characterization of cells from rat adipose tissue developing into adipocytes. J Lipid Res 19: 316– 324. CAS PubMed Web of Science®Google Scholar  Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, RJ. (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265– 275. CAS PubMed Web of Science®Google Scholar  Rebuffé‐Scrive, M. (1987) Sex steroid hormones and adipose tissue metabolism in adrenalectomized and ovariectomized rats. Acta Physiol Scand 129: 471– 477. Wiley Online Library CAS PubMed Web of Science®Google Scholar  Laurell, S., Tibbling, G. (1966) An enzymatic fluorometric micromethod for the determination of glycerol. Clin Chim Acta 13: 317– 322. Crossref CAS PubMed Web of Science®Google Scholar  Dole, V. P., Meinertz, H. (1960) Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235: 2595– 2599. CAS PubMed Web of Science®Google Scholar  Smith, U., Sjöström, L., Björntorp, P. (1972) Comparison of two methods of determining human adipose cell size. J Lipid Res 13: 822– 824. CAS PubMed Web of Science®Google Scholar  Östman, J., Arner, P., Kimura, H., Wahrenberg, H., Engfeldt, P. (1984) Influence of fasting on lipolytic response to adrenergic agonists and on adrenergic receptors in subcutaneous adipocytes. Eur J Clin Invest 14: 383– 391. Wiley Online Library PubMed Web of Science®Google Scholar  Steiner, A. L., Pagliara, A. S., Chase, L. R., Kipnis, DM. (1972) Radioimmunoassay for cyclic nucleotides. II. Adenosine 3′, 5′‐monophosphate and guanosine 3′, 5′‐monophosphate in mammalian tissues and body fluids. J Biol Chem 247: 1114– 1120. CAS PubMed Web of Science®Google Scholar  Steiner, A. L., Parker, C. W., Kipnis, DM. (1972) Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem 247: 1106– 1113. CAS PubMed Web of Science®Google Scholar  McKenzie, FR. (1988) Basic techniques to study G‐protein function. In: G Milligan eds. Signal Transduction—A Practical Approach, Part 2 31– 56. Oxford University Press New York. Google Scholar  Solomon, S. S., Sibley, S. D., Dismukes, J.R. (1991) Growth hormone‐enhanced lipolysis in the spontaneously diabetic BB rat. J Lab Clin Med 118: 99– 105. CAS PubMed Web of Science®Google Scholar  Nam, S. Y., Marcus, C. (2000) Growth hormone and adipocyte function in obesity. Horm Res 53: (Suppl 1), 87– 97. Crossref CAS PubMed Web of Science®Google Scholar  Bahouth, S. W., Malbon, CC. (1988) Subclassification of β‐adrenergic receptors of rat fat cells: a re‐evaluation. Mol Pharmacol 34: 318– 326. CAS PubMed Web of Science®Google Scholar  Granneman, J. G., Lahners, K. N., Chaudhry, A. (1992) Molecular cloning and expression of the rat β3‐adrenergic receptor. Mol Pharmacol 40: 895– 899. Web of Science®Google Scholar  Hollenga, C. H., Zaagsma, J. (1989) Direct evidence for the atypical nature of functional β‐adrenoceptors in rat adipocytes. Br J Pharmacol 98: 1420– 1424. Wiley Online Library CAS PubMed Web of Science®Google Scholar  Lacasa, D., Agli, B., Giudicelli, Y. (1985) Direct assessment of β‐adrenergic receptors in intact rat adipocytes by binding of [3H]CGP 12177. Eur J Biochem 146: 339– 346. Wiley Online Library CAS PubMed Web of Science®Google Scholar  Umekawa, T., Yoshida, T., Sakane, N., Kondo, M. (1996) Effect of CL316, 243, a highly specific β3‐adrenoceptor agonit, on lipolysis of human and rat adipocytes. Horm Metab Res 28: 394– 396. Crossref CAS PubMed Web of Science®Google Scholar  Bojanic, D., Nahorski, SR. (1983) Identification and subclassification of rat adipocyte β‐adrenoceptors using (±)‐[125I]cyanopindolol. Eur J Pharmacol 93: 235– 243. Crossref CAS PubMed Web of Science®Google Scholar  Langin, D., Portillo, M., Saulnier‐Blache, J. S., Lafontan, M. (1991) Coexistence of three beta‐adrenergic receptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199: 291– 301. Crossref CAS PubMed Web of Science®Google Scholar   •••WANT YOUR QUESTION ANSWERED?••• Create a free account at www.theprepcoachforum.com and post up your question in the Mike Arnold PED Q&A open threat!    •••SUPPORT OUR PEPTIDE/RESEARCH CHEMS SPONSORS•••   (RESEARCH CHEMS) www.maresearchchems.net___use discount code “alex15” to save off your order!   (SPECIALTY SUPPS) www.masupps.com___use discount code “alex20” to save off your order!   (BEEF) www.skinnybeef.com___use discount code “alex10” to save off your order!   •••FIND THE EPISODES•••   ITUNES:https://itunes.apple.com/us/podcast/beastfitness-radios-podcast/id1065532968   LIBSYN:http://beastfitnessradio.libsyn.com   VIMEO: www.vimeo.com/theprepcoach        •••PREP COACH APPAREL•••   https://teespring.com/stores/the-prep-coach-apparel    

In this episode, Dr. Thomas Buchheit sheds light on who are good candidates for regenerative therapies, when and where to go for such therapies, and what the various types of regen therapies there are and how they work. Check out these slides that are referenced in the interview, "What do PRP, Stem Cells, and other Regenerative Therapies Really do?" Who is Dr. Buchheit? He is Director of The Regenerative Pain Therapies Program at Duke (DukeRPTP.org). He has practiced pain management and musculoskeletal medicine for the past 20 years and has published multiple papers clarifying the underlying biochemical and inflammatory mechanisms that drive chronic pain. He previously served as Division Chief for Pain Medicine in the Duke Department of Anesthesiology prior to focusing full time on the study and development of regenerative therapies for patients with osteoarthritis. He co-founded The Regenerative Pain Therapies Program in 2018 with Dr. William Maixner with the goal of moving beyond symptom management to address the underlying causes of degenerative conditions. The objective of the Program is to develop and deploy biologically-based interventions to improve long-term joint health by changing disease course. Dr. Buchheit is currently involved with researchers in the United States and Europe, investigating the foundational immune mechanisms of pain relief with PRP, autologous conditioned serum, and stem cells, and has lectured extensively on these topics. He has mentored with Dr. Peter Wehling and is currently one of the few clinical sites in the US to offer the Autologous Conditioned Serum Program from Düsseldorf, Germany. 3 Selected Publications: 1. Buchheit T, Huh Y, Maixner W, Cheng J, Ji RR. Neuroimmune modulation of pain and regenerative pain medicine. J Clin Invest. 2020. Epub 2020/04/07. doi:10.1172/JCI134439. PubMed PMID: 32250346. 2. Buchheit T. Future therapies and the expanding role for diagnostic ultrasound. Curr Opin Anaesthesiol. 2016 Oct;29(5):582–3. PMID: 27455044 3. Yin C, Buchheit TE, Park JJ. Acupuncture for chronic pain: an update and critical overview. Curr Opin Anaesthesiol. Oct, 2017;30(5):583-592. PMID: 28719458 Complete List of Published Work in MyBibliography: https://www.ncbi.nlm.nih.gov/myncbi/thomas.buchheit.1/bibliography/public/ Recent Presentations: Translational Pain Research Symposium, Duke Kunshan University and Fudan University, Kunshan China. June 21-23, 2017. Nerve Injury and Amputation: Phenotypes, Novel Markers, and Prevention. American Pain Society Annual Meeting, Milwaukee, WI. April 3-6, 2019. Applications for Regenerative Therapies: Is the Hype Justified? World Institute of Pain World Congress, Rome Italy (Virtual). August 26-29. Stem Cells and Regenerative Medicine: Reconciling basic science, translational application, and clinical outcomes. Pain Society of the Carolinas Annual Meeting, Asheville, NC (Virtual) September 18-19, 2020. Regenerative Medicine American Society of Regional Anesthesia and Pain Medicine Annual Pain Medicine Meeting. November 19- 21, 2020. Las Vegas, Nevada (Virtual). Regenerative Medicine Lecture. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/painless-pain-management/message Support this podcast: https://anchor.fm/painless-pain-management/support

Abigail Kay, MD, MS, joins host Lorenzo Norris, MD, to discuss the treatment of patients with substance use disorders. Dr. Kay is an addiction psychiatrist at Thomas Jefferson University Hospital in Philadelphia and is associate dean of academic affairs and medical student education at Sidney Kimmel Medical College. Dr. Norris is assistant dean of student affairs, and assistant professor of psychiatry and behavioral sciences at George Washington University, Washington. Dr. Kay disclosed no conflicts of interest for the past year. Before that, she reported receiving payment from the American Society of Addiction Medicine, through a grant from the Substance Abuse and Mental Health Services Administration, to teach a free training to clinicians to be certified to prescribe buprenorphine. Dr. Norris, who also serves as medical director of psychiatric and behavioral sciences at George Washington University Hospital, disclosed no conflicts. Take-home points Substance use disorders have genetic and environmental factors. The genetic component is sometimes overlooked because the environmental factor – the exposure to using a substance – is heavily focused as the only trigger for addiction. Methadone is a pure agonist at the mu-opioid receptor so the higher dose the greater the effect. The average dose of methadone to achieve blocking of cravings, withdrawal, and opiate intoxication is 80-120 mg. Buprenorphine is a partial agonist: At low doses, it acts as an agonist, and at high doses it acts as an antagonist with quite high affinity for the receptor. As a partial agonist, it has a ceiling effect with more than 90% of opiate receptors occupied at 24 mg. Dr. Kay suggests a helpful rule of thumb is to assume that, if patients have an addiction, there’s a 50/50 chance that they have another psychiatric disorder and vice versa. With this in mind, all patients with substance use disorder should be evaluated for comorbid psychiatric disorders and underlying medical conditions. Summary Dr. Kay breaks down human cognition into the primitive brain and thoughtful brain. The primitive brain keeps us alive by preferentially focusing on sleeping, drinking, and eating. Addiction to a drug hijacks the primitive brain, making it prioritize the substance of choice above all else. Methadone is the “gold-standard” treatment for opioid use disorder in the sense that all treatments are compared with its efficacy and mechanism of action. Methadone is a pure agonist at the mu-opioid receptor, meaning the higher dose the greater the effect; the average dose of methadone is 80-120 mg. The goal of treatment is to achieve a blocking dose, meaning a dose that blocks the craving, the withdrawal, and the high if people were to use illicit opiates on top of their methadone. Methadone is administered only at federally approved sites, and one advantage is that additional services, such as counseling, can be offered on site after daily administration. Buprenorphine as a partial agonist can play both “roles” on the mu-opioid receptor. At low doses, it acts as an agonist, and at high doses, it acts as an antagonist with quite high affinity for the receptor. In addition, as a partial agonist buprenorphine has a ceiling effect: At 24 mg of buprenorphine occupies 92% of opiate receptors and at 32 mg only an additional 1% of receptors are occupied. Buprenorphine must be administered when the person is already in withdrawal, because its affinity to the receptor dislodges other opiates from the mu receptor thus precipitating withdrawal. Buprenorphine works well for individuals who would require an average 40-60 mg of methadone to achieve their blocking dose. Because of the ceiling effect, some individuals continue to crave opiates while on buprenorphine. This means that, despite the greater convenience offered by buprenorphine, it is not the treatment of choice for everyone. Naltrexone is a pure opioid antagonist requiring 10-14 days of abstinence from opiates to prevent precipitating opioid withdrawal. Naltrexone can be given as a once-monthly injection to address cravings. The greatest risk with naltrexone is that, after 1 month of treatment, people lose their tolerance and are at risk of opioid overdose if they return to their previous amount of use. References Volkow ND. Hum Genet. 2012 Jun;131(6):773-7. Volkow ND, Blanco C. J Clin Invest. 2020 Jan 2;130(1):10-3. SAMHSA.gov. Overview of MAT: https://www.samhsa.gov/medication-assisted-treatment/treatment. Jones HE et al. N Engl J Med. 2010;363:2320-31. Kay A et al. J Addict Dis. 2010 Apr;29(2):139-63. Show notes by Jacqueline Posada, MD, who is associate producer of the Psychcast and consultation-liaison psychiatry fellow with the Inova Fairfax Hospital/George Washington University program in Falls Church, Va. Dr. Posada has no conflicts of interest. *  *  * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com

Why Convalescent Plasma for COVID-19? In this episode of Ortho Science BYTES host, Matt Dawson discuss why COVID-19 Convalescent Plasma has been used as a treatment and what are the scientific and clinical basis for its use with Dr. Lily Li.   About our Speaker: Dr. Lily Li is the Medical Safety Officer at Ortho Clinical Diagnostics responsible for evaluating potential medical risks and guiding risk mitigation of all marketed products. She also serves as a Medical Director at Medical and Scientific Affairs providing evidence-based support to Ortho’s current and future products. Prior to joining Ortho, Lily had ten years of pharmaceutical R&D experience in Johnson & Johnson and led and advanced multiple programs of biologics and cell therapies through development. Lily obtained her Medical Degree from Peking University, China, and her Ph.D. in Immunology from the University of Alberta, Canada. She completed her post-doctoral training at the Scripps Research Institutes, San Diego. Lily is the author of more than 40 scientific articles and has filed 17 patent applications. References and Links: Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma; Shen at al. JAMA. 2020;323(16):1582-1589. Published online March 27, 2020.The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study, Duan et al, Mar 2020, medRxiv preprint doi: https://doi.org/10.1101/2020.03.16.20036145Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial, Li et al, JAMA, 2020 Jun 3. doi: 10.1001/jama.2020.10044.Convalescent plasma treatment of severe COVID-19: A matched 1 control study, S. T. H. Liu, et al, May 22, 2020, medRxiv preprint doi: https://doi.org/10.1101/2020.05.20.20102236. Convalescent Plasma to Treat COVID-19. Possibilities and Challenges; John D. Roback, MD, PhD; Jeannette Guarner, MD. JAMA April 28, 2020 Volume 323, Number 16The convalescent sera option for containing COVID-19 Arturo Casadevall, Liise-anne Pirofski. J Clin Invest. 2020;130(4):1545-1548. FDA site https://www.fda.gov/

With COVID-19 and the question of whether glucocorticoids could be beneficial, this episode digs into the data on the use of glucocorticoids in the setting of infections, from pneumonia and septic arthritis, to meningitis and septic shock. Intro :11 In this episode :25 The first published case series of patients with serious infection 6:45 Otolaryngologic infections 7:43 Pneumonia, malaria and flu 8:26 Cortisone in strep throat 9:22 Major severe infections 11:26 A review article 12:12 Specific organ systems 13:25 Dexamethasone for bacterial meningitis 25:28 Septic shock 26:19 Dearth of data on glucocorticoids for influenza 32:10 Summary and take-home 35:19 Disclosure: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Annane D, et al. JAMA. 2002;288:862-871. Annane D, et al. N Engl J Med. 2018;378:809-818. Bennett IL, et al. JAMA. 1963;183:462-465. Blum CA, et al. Lancet. 2015;385:1511-1518. de Gans J, van de Beek D. N Engl J Med. 2002;347:1549-1556. Dellinger RP, et al. Crit Care Med. 2013;41:580-637. Fogel I, et al. Pediatrics. 2015;136:e776. Hahn EO, et al. J Clin Invest. 1951;30:274-281. Hartman FA, Merle Scott WJ. Proc Soc Exp Biol and Med. 1931;28:478-479. Hinshaw LB, et al. J Surg Res. 1980;28:151-170. Nedel WL, et al. World J Crit Care Med. 2016;5:89-95. Odio CM, et al. Pediatr Infect Dis J. 2003;22:883-888. Perla D, Marmorston J. Endocrinology. 1940;27:368-374. Stern A, et al. Cochrane Database Syst Rev. 2017;12:doi:10.1002/14651858.CD007720.pub3 Venkatesh B, et al. N Engl J Med. 2018;378:797-808. Wenner WF, Cone AJ. Arch Otolaryngol. 1934;20:178-187. Whitehead KW, Smith C. Proc Soc Expert Biol and Med. 1932;29:672-673. Wysenbeek AJ, et al. Ann Rheum Dis. 1998;57:687–690.  Zhou Y, et al. Sci Rep. 2020;10:https://doi.org/10.1038/s41598-020-59732-7.

Sodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Chemotherapy Induced Cardiotoxicity? Dr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians References Scafoglio C, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015 Scafoglio CR,  et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018 Martinez CA, Scafoglio C. Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules. 2020 Paternostro G, Camici PG, Lammerstma AA, Baliga RR, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest. 1996;98(9):2094‐2099. Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure [published online ahead of print, 2020 May 6]. JAMA Cardiol. 2020 Fang JC. Heart-Failure Therapy - New Drugs but Old Habits?. N Engl J Med. 2019 McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995‐2008.

Nebojša je odsutan. Miloš pokušava da prevede svoje predavanje o Covid-19 i pacijentima sa rakom na srpski. Izvori: 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. 2. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020:eabb2762. 3. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3. 4. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020. 5. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020:eabb3221. 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020 7. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020. 8. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama. 2020. 9. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2020:2020.04.23.20076042. 10. Collaborative TO, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020:2020.05.06.20092999. 11. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020. 12. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020. Linkovi: 1. The Covid-19 and cancer consortium (https://ccc19us.org) 2. ASCO Covid-19 resources (https://www.asco.org/asco-coronavirus-information) 3. ASH Covid-19 resources (https://www.hematology.org/covid-19)

Ouça e se atualize sobre o novo Coronavírus com o TdC! O episódio foi dividido em duas partes, essa discute o manejo do paciente com suspeita de COVID-19. MINUTAGEM Abordagem dos Casos Suspeitos - Parte 1 [01:15]. Apresentação do Episódio [04:00]. Definição de Caso Suspeito [09:25]. Quadro Clínico [13:00]. Atendimento inicial ao Caso Suspeito [15:00]. Tipos de máscaras [19:30]. Alterações Laboratoriais e de Imagem [21:30]. Estratificação e Manejo pela OMS [27:00]. Medicamentos em estudo atualmente [32:00]. Vacina [34:40]. REFERÊNCIAS: 1. NI, Yue-Nan et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care, v. 23, n. 1, p. 99, 2019. 2. RUSSELL, Clark D.; MILLAR, Jonathan E.; BAILLIE, J. Kenneth. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet, v. 395, n. 10223, p. 473-475, 2020. FANG, Lei; 3. KARAKIULAKIS, George; ROTH, Michael. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet Respiratory Medicine, 2020. 4. LIU, Weiyong et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. New England Journal of Medicine, 2020. 5. Sociedade internacional de ultrassom em GO ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol. 2020 Mar 11. doi: 10.1002/uog.22013. 6. FAVRE, Guillaume et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. The Lancet Infectious Diseases, 2020. 7. CHEN, Huijun et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet, 2020. 8. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Mar 13. pii: 138003. doi: 10.1172/JCI138003. 9. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak Interim guidance 29 January 2020 - World Health Organization. 10. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 1.2. 11. “Field Briefing: Diamond Princess COVID-19 Cases, 20 Feb Update” Acessado em: https://www.niid.go.jp/niid/en/2019-ncov-e/9407-covid-dp-fe-01.html. 12. https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html 12. https://saude.rs.gov.br/upload/arquivos/202002/12090034-coronavirus-isolamento-domiciliar-1.pdf. 13. Markel, Howard, et al. "Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic." Jama 298.6 (2007): 644-654. 14. Wang, Wenling, et al. "Detection of SARS-CoV-2 in Different Types of Clinical Specimens." JAMA (2020). 15. Lai, Shengjie, et al. "Effect of non-pharmaceutical interventions for containing the COVID-19 outbreak: an observational and modelling study." medRxiv (2020). 16. YAN, Gabriel et al. Covert COVID-19 and false-positive dengue serology in Singapore. The Lancet Infectious Diseases, 2020. 17. WANG, Dawei et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama, 2020. 18. ZHOU, Fei et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 2020.

Ouça e se atualize sobre o novo Coronavírus com o TdC! O episódio foi dividido em duas partes, essa discute como está ocorrendo a pandemia e as medidas que podemos utilizar para o seu controle. MINUTAGEM [0:30] Situação Atual [02:20] Letalidade [06:00] Brasil vs Itália [09:30] Quarentena e Isolamento [15:00] Transmissão assintomática [17:40] Medidas Não Farmacológicas [28:00] Persistência do COVID-19 nas superfícies [30:30] IECA/BRA/Ibuprofeno [33:00] Crianças [34:10] Salves REFERÊNCIAS: 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi:10.1001/jama.2020.2648 2. RUSSELL, Clark D.; MILLAR, Jonathan E.; BAILLIE, J. Kenneth. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet, v. 395, n. 10223, p. 473-475, 2020. FANG, Lei; 3. KARAKIULAKIS, George; ROTH, Michael. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet Respiratory Medicine, 2020. 4. LIU, Weiyong et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. New England Journal of Medicine, 2020. 5. Sociedade internacional de ultrassom em GO ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol. 2020 Mar 11. doi: 10.1002/uog.22013. 6. FAVRE, Guillaume et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. The Lancet Infectious Diseases, 2020. 7. CHEN, Huijun et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet, 2020. 8. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Mar 13. pii: 138003. doi: 10.1172/JCI138003. 9. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak Interim guidance 29 January 2020 - World Health Organization. 10. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak. Interim guidance 29 January 2020. WHO reference number: WHO/nCov/IPC_Masks/2020. 11. Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. Interim guidance 17 March 2020. WHO reference number: WHO/nCov/IPC/HomeCare/2020.3 12. https://saude.rs.gov.br/upload/arquivos/202002/12090034-coronavirus-isolamento-domiciliar-1.pdf. 13. Markel, Howard, et al. "Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic." Jama 298.6 (2007): 644-654. 14. Wang, Wenling, et al. "Detection of SARS-CoV-2 in Different Types of Clinical Specimens." JAMA (2020). 15. Lai, Shengjie, et al. "Effect of non-pharmaceutical interventions for containing the COVID-19 outbreak: an observational and modelling study." medRxiv (2020). 16. NI, Yue-Nan et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care, v. 23, n. 1, p. 99, 2019.

Episode 248 is a brief overview and breakdown on the all new formula for ProjectAD's RAGING FULL! This is their intra workout carbohydrate and hydration blend that has some awesome new aspects to it! This is a brief overview which should help you guys understand why I am a huge fan of this new formula! There will be an extreme in depth breakdown in the future for those science nerds like me that LOVE the details!   INTRAWORKOUT CARBOHYDRATE/AMINO ACID REFERENCES Bird SP, et al. Liquid carbohydrates/essential amino acid ingestion during a short-term bout of resistance exercise suppresses myofibrillar protein degradation. Metabolism. 2006 May;55(5):570-7.   Bloom PC, et al.  Effect of different post-exercise sugar diets on the rate of muscle glycogen synthesis.  Med Sci Sports Exerc.  1987 Oct;19(5):491-6.   Desbrow B, et al. Carbohydrate-electrolyte feedings and 1h time trial cycling performance. Int J Sport Nutr Exerc Metab. 2004 Oct;14(5):541-9.   Erith S, et al.  The effect of high carbohydrate meals with different glycemic indices on recovery of performance during prolonged   Haff GG, et al. Carbohydrate supplementation and resistance training. J Strength Cond Res. 2003 Feb;17(1):187-96.   Ivy JL, et al. Muscle glycogen synthesis after exercise: effect of time of carbohydrate ingestion. J Appl Physiol. 1988 Apr;64(4):1480-5.   Jentjens RL, et al.  Oxidation of combined ingestion of glucose and fructose during exercise.  J Apply Physiol.  2004 Apr;96(4):1277-84.   Jentjens RL, et al.  Oxidation of exogenous glucose, sucrose and maltose during prolonged cycling exercise.  J Apply Physiol.  2004 Apr;96(4):1285-91.   Jentjens RL, Jeukendrup AE.  High rates of exogenous carbohydrate oxidation from a mixture of glucose and fructose ingested during prolonged cycling exercise.  Br J Nutr.  2005 Apr;93(4):485-92   Jeukendrup AE. Carbohydrate during exercise and performance. Nutrition. 2004 Jul-Aug;20(7-8):669-77.   Keizer HA, et al.  Influence of liquid and solid meals on muscle glycogen resynthesis, plasma fuel hormone response, and maximal physical working capacity.  Int J Sports Med.  1987 Apr;8(2):99-104. https://www.ncbi.nlm.nih.gov/pubmed/25080121 https://www.jstage.jst.go.jp/article/fstr/21/3/21_499/_html   Ferrando, A.A., et al., Oral branched-chain amino acids decrease whole-body proteolysis. JPEN. Journal of parenteral and enteral nutrition, 1995. 19(1): p. 47-54. http://www.ncbi.nlm.nih.gov/pubmed/7658600   Ruderman, N.B., et al., Regulation of alanine formation and release in rat muscle in vivo: effect of starvation and diabetes. The American journal of physiology, 1977. 233(2): p. E109-14. http://www.ncbi.nlm.nih.gov/pubmed/888947   Shimomura, Y., et al., Exercise promotes BCAA catabolism: effects of BCAA supplementation on skeletal muscle during exercise. The Journal of nutrition, 2004. 134(6 Suppl): p. 1583S-1587S. http://www.ncbi.nlm.nih.gov/pubmed/15173434   Fujii, H., et al., Branched-chain alpha-keto acid dehydrogenase kinase content in rat skeletal muscle is decreased by endurance training. Biochemistry and molecular biology international, 1998. 44(6): p. 1211-6. http://www.ncbi.nlm.nih.gov/pubmed/9623776   Lamont, L.S., et al., Comparison of leucine kinetics in endurance-trained and sedentary humans. Journal of applied physiology, 1999. 86(1): p. 320-5. http://www.ncbi.nlm.nih.gov/pubmed/9887146   Wagenmakers, A.J., et al., Carbohydrate supplementation, glycogen depletion, and amino acid metabolism during exercise. The American journal of physiology, 1991. 260(6 Pt 1): p. E883-90. http://www.ncbi.nlm.nih.gov/pubmed/2058665   Louard, R.J., et al., Effect of infused branched-chain amino acids on muscle and whole-body amino acid metabolism in man. Clinical science, 1990. 79(5): p. 457-66. http://www.ncbi.nlm.nih.gov/pubmed/2174312   Gualano, A.B., et al., Branched-chain amino acids supplementation enhances exercise capacity and lipid oxidation during endurance exercise after muscle glycogen depletion. The Journal of sports medicine and physical fitness, 2011. 51(1): p. 82-8. http://www.ncbi.nlm.nih.gov/pubmed/21297567   Shimomura, Y., et al., Branched-chain amino acid supplementation before squat exercise and delayed-onset muscle soreness. International journal of sport nutrition and exercise metabolism, 2010. 20(3): p. 236-44. http://www.ncbi.nlm.nih.gov/pubmed/20601741 Coombes, J.S. and L.R. McNaughton, Effects of branched-chain amino acid supplementation on serum creatine kinase and lactate dehydrogenase after prolonged exercise. The Journal of sports medicine and physical fitness, 2000. 40(3): p. 240-6. http://www.ncbi.nlm.nih.gov/pubmed/11125767   Bolster, D.R., et al., Regulation of protein synthesis associated with skeletal muscle hypertrophy by insulin-, amino acid- and exercise-induced signalling. The Proceedings of the Nutrition Society, 2004. 63(2): p. 351-6. http://www.ncbi.nlm.nih.gov/pubmed/15294054   Atherton, P.J., et al., Distinct anabolic signalling responses to amino acids in C2C12 skeletal muscle cells. Amino acids, 2010. 38(5): p. 1533-9. http://www.ncbi.nlm.nih.gov/pubmed/19882215   Kimball, S.R. and L.S. Jefferson, Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. The Journal of nutrition, 2006. 136(1 Suppl): p. 227S-31S. http://www.ncbi.nlm.nih.gov/pubmed/16365087   Gran, P. and D. Cameron-Smith, The actions of exogenous leucine on mTOR signalling and amino acid transporters in human myotubes. BMC physiology, 2011. 11: p. 10. http://www.ncbi.nlm.nih.gov/pubmed/21702994   Greiwe, J.S., et al., Leucine and insulin activate p70 S6 kinase through different pathways in human skeletal muscle. American journal of physiology. Endocrinology and metabolism, 2001. 281(3): p. E466-71. http://www.ncbi.nlm.nih.gov/pubmed/11500301   Atherton, P.J., et al., Muscle full effect after oral protein: time-dependent concordance and discordance between human muscle protein synthesis and mTORC1 signaling. The American journal of clinical nutrition, 2010. 92(5): p. 1080-8. http://www.ncbi.nlm.nih.gov/pubmed/20844073   Matthews, D.E., Observations of branched-chain amino acid administration in humans. The Journal of nutrition, 2005. 135(6 Suppl): p. 1580S-4S. http://www.ncbi.nlm.nih.gov/pubmed/15930473   Paddon-Jones, D., et al., Amino acid ingestion improves muscle protein synthesis in the young and elderly. American journal of physiology. Endocrinology and metabolism, 2004. 286(3): p. E321-8. http://www.ncbi.nlm.nih.gov/pubmed/14583440     Wolfe, R.R., Effects of amino acid intake on anabolic processes. Canadian journal of applied physiology = Revue canadienne de physiologie appliquee, 2001. 26 Suppl: p. S220-7. http://www.ncbi.nlm.nih.gov/pubmed/11897897   Floyd, J.C., Jr., et al., Evidence That Insulin Release Is the Mechanism for Experimentally Induced Leucine Hypoglycemia in Man. J Clin Invest, 1963. 42: p. 1714-9. http://www.ncbi.nlm.nih.gov/pubmed/14083162   Chow, L.S., et al., Mechanism of insulin’s anabolic effect on muscle: measurements of muscle protein synthesis and breakdown using aminoacyl-tRNA and other surrogate measures. Am J Physiol Endocrinol Metab, 2006. 291(4): p. E729-36. http://www.ncbi.nlm.nih.gov/pubmed/16705065   Shimomura, Y., et al., Nutraceutical effects of branched-chain amino acids on skeletal muscle. The Journal of nutrition, 2006. 136(2): p. 529S-532S. http://www.ncbi.nlm.nih.gov/pubmed/16424141    •••SUPPORT OUR SPONSOR••• (COACHING) Alex - www.theprepcoach.com   (FREE OPEN FORUM w/ EXCLUSIVE VIDEOS) http://www.theprepcoachforum.com (SUPPLEMENTS) www.projectad.me___use discount code “BFR25” to save off your order! www.maresearchchems.com___use discount code “alex15” to save off your order! www.masupps.com___use discount code “alex20” to save off your order! (INJECTABLE L-CARNITINE) www.synthetek.com___use discount code “alexkikel” to save off your order! (BULK SUPPLEMENTS) www.truenutrition.com___use discount code “AXK5” to save off your order!   •••FIND THE EPISODES••• ITUNES:https://itunes.apple.com/us/podcast/beastfitness-radios-podcast/id1065532968 LIBSYN:http://beastfitnessradio.libsyn.com VIMEO: www.vimeo.com/theprepcoach YOUTUBE: https://www.youtube.com/c/ThePrepCoach    •••PREP COACH APPAREL••• https://teespring.com/stores/the-prep-coach-apparel

This ripping yarn delves into the history of tumor necrosis factor in relation to rheumatoid arthritis with emphasis on the original studies that set the stage for the use of TNF inhibition in RA.  Intro :11 What we’ll cover here :16 Recap of Part 1 1:25 What I discovered when doing this episode 1:22 What this episode won’t address 2:40 Let the tale begin 3:12 A look at matrix metalloproteinases 3:32 A breakthrough in understanding RA 6:28 Two key players: Dr. Mark Feldman and Dr. Ravinder Maini 6:53 The first cytokine research conducted in RA: IL-1 8:00 The next cytokine: Tumor necrosis factor 11:16 What do we know about cytokine production within the joint? 14:33 IL-6 and TGF-beta 19:16 A bit about IL-10 23:57 *Visit Healio.com/rheum for daily news and updates* How do we choose which cytokines to block to make improvements in RA? 25:16 What about in vivo data? 29:45 The history of infliximab 34:00 Infliximab is approved for RA treatment 45:13 TNF in RA: from bedside, to bench then back to bedside 46:06 It’s important to recognize the researchers who discovered these pathways 46:18 Remember the scientists next time you prescribe a TNF inhibitor 47:05 Read the latest news and commentary on Healio.com/rheumatology and Follow us on Twitter @HealioRheum and @HRheuminations for updates 47:34 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum References: Brennan FM, et al. J Autoimmun. 1989;2 Suppl:177-186. Brennan FM, et al. Lancet. 1989;2:244-247. Butler MD, et al. Eur Cytokine Netw. 1995;6:225-230. Chu CQ, et al. Arthritis Rheum. 1991;34:1125-1132. Dayer JM, et al. J Exp Med. 1985;162:2163-2168. Di Giovine FS, et al. Ann Rheum Dis. 1988;47:768-772. Feldmann, M. Nat Rev Immunol. 2002;2:364-371. Feldmann M, Maini SR. Immunol Rev. 2008;223:7-19. Fontana A, et al. Rheumatol Int. 1982;2:49-53. Haworth C, et al. Eur J Immunol. 1991;21:2575-9. Houssiau FA, et al. Arthritis Rheum. 1988;31:784-8. Keffer J, et al. EMBO J. 1991;10:4025-4031. Kulkarni AB, Karlsson S. Am J Pathol. 1993;143:3-9. Kuruvilla AP, et al. PNAS. 1991;88:2918-2921. Maini RN, et al. Arthritis Rheum. 1998;41:1552-1563. Malaviya AN, Mehra NK. Indian J Med Res. 2018;148:263–278. McInnes IB, Schett G. Nat Rev Immunol. 2007;7:429-442. Mitchison NA, Medawar PB. Proc R Soc Lond [Biol]. 1964;https://doi.org/10.1098/rspb.1964.0093. Pettipher ER, et al. Proc Natl Acad Sci U S A. 1986;83:8749-8753. The Beautiful Cure: The Revolution in Immunology and What It Means for Your Health, University of Chicago Press, Chicago, 2018. Williams RO, et al. Proc Natl Acad Sci U S A. 1992;89:9784-9788. Xu WD, et al. J Clin Invest. 1989;83:876-882.

This episode: Modifying mice's microbial communities increased mouse survival before a transplantation was rejected by their immune system! Download Episode (9.6 MB, 10.5 minutes) Show notes: News item Journal Paper: Lei YM, Chen L, Wang Y, Stefka AT, Molinero LL, Theriault B, Aquino-Michaels K, Sivan AS, Nagler CR, Gajewski TF, Chong AS, Bartman C, Alegre M-L. 2016. The composition of the microbiota modulates allograft rejection. J Clin Invest 126:2736–2744. Other interesting stories: CRISPR system can be used to record info in cells (paper) The history of beer yeasts Bacteria could help treat citrus tree disease (paper) Some viruses bud off from Archaea like in eukaryotes (paper) Infant microbe communities different with vs. without eczema (paper)   Post questions or comments here or email to bacteriofiles at gmail dot com. Thanks for listening! Subscribe: iTunes, RSS, Google Play. Support the show at Patreon, or check out the show at Twitter or Facebook  

Consider the classic understanding that high carbohydrate intakes are necessary for optimal endurance performance. What if that failed to take into account the physiological changes that occur with adaptation to low carbohydrate diets? In this podcast, @JohannWindt interviews physician-researcher Dr. Stephen Phinney about his last 30 years of research into low-carb ketogenic diets. Highlights include the previously undocumented levels of during exercise fat oxidation seen in endurance athletes adapted to a low carbohydrate diet. He also touches on ketogenic diets’ potential benefits in other sporting contexts, addresses common criticisms, and looks ahead to future research questions in the field. Further reading and papers discussed in the podcast are included below. Vermont and MIT Study Dr. Phinney’s original two studies on low carbohydrate performance. Original two low carb performance studies. http://www.metabolismjournal.com/article/0026-0495%2883%2990105-1/abstract http://www.ncbi.nlm.nih.gov/pmc/articles/PMC371554/ Phinney SD et al. The human metabolic response to chronic ketosis without caloric restriction: physical and biochemical adaptation. Metabolism 1983;32:757-68. http://www.metabolismjournal.com/article/0026-0495%2883%2990105-1/abstract Phinney SD et al. capacity for moderate exercise in obese subjects after adaptation to a hypocaloric, ketogenic diet. J Clin Invest 1980;66:1152-61. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC371554/ The gymnast study mentioned in the podcast: Paoli et al. Ketogenic diet does not affect strength performance in elite artistic gymnasts. J Int Soc Sports Nutr 2012; 9: 34. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411406/ Significant decrease in inflammation shown in low carb diets by Forsythe, Phinney, et al.Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids 2008;43:65-77. http://link.springer.com/article/10.1007/s11745-007-3132-7?no-access=true Prof Phinney’s recent BJSM Editorial: Noakes T, Volek JS, Phinney SD. Low-carbohydrate diet for athletes: what evidence? Br J Sports Med 2014 http://bjsm.bmj.com/content/early/2014/05/26/bjsports-2014-093824.extract Prof Phinney and Volek’s website– Art and Science of Low Carbohydrate Living/Performance http://www.artandscienceoflowcarb.com/ In the August 2015 issue of BJSM you’ll find a series of paper on weight loss and physical activity: http://bjsm.bmj.com/content/49/14.toc Dr Aseem Malhotra’s paper: It’s time to bust the myth of physical inactivity and obesity: you can’t outrun a bad diet (if you want to be thin) http://bjsm.bmj.com/content/49/15/967.full (OPEN ACCESS) Coauthors are Professor Phinney and Professor Timothy Noakes. Professor Stephen Blair’s rebuttal: Physical inactivity and obesity is not a myth: Dr Steven Blair comments on Dr Aseem Malhotra's editorial http://bjsm.bmj.com/content/49/15.toc Professor Kamal Mahtani’s editorial: Physical activity and obesity editorial: is exercise pointless or was it a pointless exercise? http://bjsm.bmj.com/content/49/15/969.extract Two relevant BJSM podcasts include: 1) Professor Tim Noakes interviewed by Professor Peter Brukner http://ow.ly/PQlld 2) Dr Aseem Malhotra discussing the debate around his editorial above http://ow.ly/PQlNL BJSM editors appreciate that nutrition is a controversial issue (not sure why, but that’s OK) so please note the Prof Phinney’s competing interests are listed in http://bjsm.bmj.com/content/49/15/967.full BJSM revels in debate and publishes quality material. Hence, you can see divergent views represented above and we have commissioned an editorial from respected scientists who feel that protein, or carbohydrate, deserves greater prominence. You submissions are welcome via the BJSM’s various channels – ‘print’, rapid response, blog, Google plus community, twitter, Facebook. Or email karim.khan@ubc.ca